Intra-aortic Balloon Pump

Quick Answer

Intra-aortic balloon pump (IABP) is a mechanical circulatory support device that provides diastolic augmentation and afterload reduction through counterpulsation. A helium-filled balloon positioned in the descending thoracic aorta inflates during diastole (augmenting coronary perfusion) and deflates just before systole (reducing left ventricular afterload). Indications include cardiogenic shock, acute mitral regurgitation, high-risk PCI, and bridge to advanced therapies. Despite widespread historical use, the IABP-SHOCK II trial demonstrated NO mortality benefit in acute myocardial infarction-related cardiogenic shock. [1,2]

Mechanism of action:

Diastolic augmentation: Balloon inflation at dicrotic notch increases aortic diastolic pressure by 15-20 mmHg → enhanced coronary artery perfusion [3,4]
Afterload reduction: Balloon deflation before aortic valve opening decreases systolic pressure by 5-10 mmHg → reduced left ventricular wall stress and myocardial oxygen demand [3,4]
Decreased LVEDP: Reduced left ventricular end-diastolic pressure (5-10 mmHg reduction) → improved subendocardial perfusion [3,5]

Timing principles:

Inflation: Occurs at the dicrotic notch on arterial waveform (aortic valve closure)
Deflation: Occurs just before systolic upstroke (prior to aortic valve opening)
Assist ratio: Typically 1:1 (full support) → 1:2 (weaning) → 1:4 (trial off) [6]

Key contraindications:

Absolute: Aortic regurgitation (balloon deflation worsens diastolic backflow), aortic dissection (risk of propagation), severe aortic aneurysm/disease, severe peripheral vascular disease [7,8]
Relative: Coagulopathy (INR greater than 1.5), active bleeding, sepsis, severe peripheral artery disease [7]

Complications:

Limb ischemia: 1-5% incidence; requires vigilance, compartment pressure monitoring [9,10]
Stroke: 1-3% incidence (atheroembolic or hypoperfusion-related) [11]
Aortic injury: 0.5-1% (dissection, perforation, rupture) [12]
Hemolysis: Platelet consumption, mechanical hemolysis from balloon motion [13]

CICM Exam Focus

Key High-Yield Points

IABP-SHOCK II trial is practice-changing: Randomized 600 patients with AMI-related cardiogenic shock to IABP vs optimal medical therapy; 30-day mortality 39.7% vs 41.3% (p=0.69) - NO mortality benefit; IABP now classified as "class III" (harmful/no benefit) in ESC guidelines for this indication [1,2,14]
Mechanism requires understanding of timing: Balloon inflation MUST occur at dicrotic notch (diastole) and deflation MUST occur before systolic upstroke; incorrect timing (late inflation or early deflation) can WORSEN hemodynamics [3,6]
Aortic regurgitation is absolute contraindication: IABP deflates in diastole, which is when regurgitant flow would normally occur; removing counterpulsation exacerbates volume overload and pulmonary edema [7,8]
Coronary perfusion pressure enhancement: Diastolic augmentation increases aortic root pressure → improves coronary artery blood flow (primarily occurs during diastole); most beneficial for right coronary artery (dominant in 80%) supplying inferior wall [3,4]
Afterload reduction physiology: Peak systolic pressure reduction decreases left ventricular wall stress (Law of Laplace: Wall stress = [Pressure × Radius] / [2 × Wall thickness]); reduces myocardial oxygen consumption by 10-20% [3,5]
Limb ischemia requires vigilance: 1-5% incidence; check pedal pulses hourly, consider duplex ultrasound if Doppler signals decrease; early removal or repositioning may prevent compartment syndrome and amputation [9,10]
Hemodynamic effects are modest: Compared to VA-ECMO (cardiac output increase 2-3 L/min), IABP provides modest cardiac output increase of 0.5-1.0 L/min; NOT sufficient for severe cardiogenic shock requiring greater than 2 L/min support [15,16]
Bridge-to-bridge therapy: IABP may be used as temporary stabilization while arranging advanced mechanical circulatory support (VA-ECMO, Impella, LVAD) or transplant evaluation; typically used for 24-72 hours [17,18]
Weaning protocol: 1:1 → 1:2 (6-12 hours) → 1:4 (trial off 30-60 min) → removal; monitor for hemodynamic deterioration (HR increase greater than 20%, SBP decrease greater than 20 mmHg, CI decrease greater than 0.5 L/min/m²) [6,19]
Device selection: Catheter size 7.5-8.0 Fr (smaller reduces limb ischemia risk); balloon volume 30-40 cc (based on patient height: below 163 cm = 30 cc, 163-183 cm = 34 cc, greater than 183 cm = 40 cc) [20]

Common Viva Themes

Mechanism of action: Diastolic augmentation and afterload reduction with pressure tracings
IABP-SHOCK II trial implications and current guideline recommendations
Indications vs contraindications (especially aortic regurgitation and aortic dissection)
Timing of inflation/deflation with arterial waveform interpretation
Complications (limb ischemia, aortic injury, stroke, hemolysis) and management
Weaning criteria and protocol
Comparison with other mechanical circulatory support devices (VA-ECMO, Impella)
Hemodynamic monitoring during IABP therapy
Procedural steps for insertion (femoral approach, Seldinger technique)
Management of balloon malfunction or failure

Common Pitfalls

Assuming IABP provides significant cardiac output support (modest effect compared to VA-ECMO) [15]
Forgetting that aortic regurgitation is absolute contraindication (common viva question) [7]
Incorrect timing: Late inflation (increases afterload) or early deflation (decreases diastolic augmentation) [3,6]
Missing that IABP-SHOCK II showed NO mortality benefit in AMI-related cardiogenic shock [1,2]
Not recognizing that limb ischemia may present subtly (decreased Doppler signals before pulse loss) [9,10]
Overestimating IABP's utility in severe cardiogenic shock (should consider VA-ECMO instead) [15,16]
Forgetting that balloon position should be 1-2 cm distal to left subclavian artery (verify on CXR) [20]
Not adjusting heparin infusion for ACT monitoring (target 180-200 seconds) [21]
Removing IABP before adequate anticoagulation reversal (thrombosis risk) [22]
Missing that IABP is contraindicated in severe aortic stenosis (reduces coronary perfusion pressure) [23]

Clinical Overview

Definition and Classification

Intra-aortic balloon pump (IABP) is a form of mechanical circulatory support that utilizes counterpulsation to improve hemodynamics in patients with compromised cardiac function. The device consists of a catheter-mounted balloon positioned in the descending thoracic aorta, which is connected to a console driving system that synchronizes balloon inflation/deflation with the cardiac cycle. [3,4]

Classification by support mechanism:

Counterpulsation: Balloon inflates during diastole, deflates during systole (out-of-phase with native cardiac output)
Diastolic augmentation: Increases aortic root pressure during diastole → improved coronary perfusion
Afterload reduction: Decreases aortic systolic pressure during systole → reduced LV work [3,4]

IABP catheter types:

Fiber-optic (most common): Balloon volume 30-40 cc, catheter size 7.5-9.0 Fr, rapid response time (below 40 ms)
Fluid-filled (older): Slower response, less accurate timing, largely replaced by fiber-optic [20]

Console driving system:

Helium-driven: Helium gas (low viscosity, rapid transfer) inflates/deflates balloon
Synchronization: Uses ECG trigger (R-wave) or arterial pressure trigger (dicrotic notch)
Backup modes: Internal timing (fixed rate) if ECG/pressure signal lost [6,20]

Historical Context

Development timeline:

1952: Kantrowitz describes "diastolic augmentation" concept in animal models
1962: Moulopoulus develops first IABP prototype
1968: First clinical IABP use in cardiogenic shock post-MI (Kantrowitz)
1970s-1980 s: Widespread adoption in cardiac surgery and cardiogenic shock
2012: IABP-SHOCK II trial challenges utility in AMI-related cardiogenic shock [1,3]

Clinical evolution:

Initially hailed as breakthrough therapy for cardiogenic shock
Standard of care for decades (1980s-2010s)
Practice-changing trial (IABP-SHOCK II) led to guideline downgrading
Current role: Adjunctive therapy, bridge to advanced therapies, specific indications [1,14,24]

Epidemiology and Utilization

Global utilization trends:

Declining use: IABP usage decreased by ~50% after IABP-SHOCK II (2012) publication
Regional variation: Higher utilization in Asia-Pacific vs Europe/North America
Current indications: Primarily mechanical complications of MI (VSD, papillary muscle rupture), high-risk PCI, bridge to transplant/VAD [24,25]

Patient population:

Age: Median 65-75 years (reflects MI and heart failure demographics)
Gender: Male predominance (60-70%) - higher CAD burden
Comorbidities: Diabetes (30-40%), prior MI (20-30%), CKD (15-25%) [9,26]

Procedural statistics:

Success rate: 95-98% insertion success (experienced operators)
Duration: Median 2-5 days (range: hours to weeks)
Weaning success: 70-80% successfully weaned and removed [9,19]

Mechanism of Action

Hemodynamic Physiology

Diastolic Augmentation (Coronary Perfusion):

Timing: Balloon inflates at dicrotic notch (aortic valve closure)
Pressure effect: Increases aortic diastolic pressure by 15-20 mmHg
Coronary blood flow: 70-80% of coronary perfusion occurs during diastole; increased diastolic pressure → 10-20% increase in coronary artery blood flow
Benefit: Enhanced myocardial oxygen delivery, especially to ischemic territories (right coronary artery - inferior wall) [3,4]

Afterload Reduction (LV Work):

Timing: Balloon deflates just before systolic upstroke (aortic valve opens)
Pressure effect: Decreases systolic arterial pressure by 5-10 mmHg
LV wall stress: Reduced according to Law of Laplace (Wall stress = [Pressure × Radius] / [2 × Wall thickness])
Myocardial oxygen consumption: Decreases by 10-20% [3,5]

Stroke Volume and Cardiac Output:

Forward flow: IABP increases stroke volume by 5-15 mL/beat
Cardiac output: Modest increase of 0.5-1.0 L/min (compared to VA-ECMO 2-3 L/min increase)
Net effect: Reduced LVEDP (5-10 mmHg) + increased forward flow → improved hemodynamics [3,15]

Left Ventricular Unloading:

LVEDP reduction: Decreases from 25-30 mmHg to 15-20 mmHg
Pulmonary capillary wedge pressure: Decreases by 5-10 mmHg
Pulmonary edema: Reduced hydrostatic pressure → improved oxygenation [3,5]

Counterpulsation Timing

Inflation Timing:

Ideal: At dicrotic notch (aortic valve closure)
Early inflation: Increases afterload (inflates before aortic valve closes) → WORSE hemodynamics
Late inflation: Reduces diastolic augmentation (inflates after aortic valve closes) → Less benefit
Trigger: ECG R-wave delay (typically 100-150 ms after QRS complex) [6,20]

Deflation Timing:

Ideal: Just before systolic upstroke (prior to aortic valve opening)
Early deflation: Decreases diastolic augmentation prematurely → Less benefit
Late deflation: Increases afterload (balloon still inflated when aortic valve opens) → WORSE hemodynamics, myocardial ischemia
Trigger: Pressure trigger (dicrotic notch to systolic upstroke) [6,20]

Assist Ratios:

1:1: Full support (balloon inflates every beat)
1:2: Partial support (every 2nd beat) - weaning
1:3: Partial support (every 3rd beat) - advanced weaning
1:4: Trial off - assess stability before removal
1: No balloon inflation (standby mode) [6,19]

Arterial Waveform Changes:

Augmented diastolic pressure:

Unassisted: Diastolic pressure 60-70 mmHg (typical)
Assisted: Diastolic pressure 75-90 mmHg (augmented peak)
Augmented diastolic peak: Should be > systolic peak (diastolic augmentation success marker) [6]

Reduced systolic pressure:

Unassisted: Systolic pressure 120-140 mmHg (typical)
Assisted: Systolic pressure 110-130 mmHg (reduced by 5-10 mmHg) [6]

Assist spike: Visible on arterial waveform when balloon inflates (sharp upstroke after dicrotic notch) [6]

Hemodynamic Monitoring During IABP

Arterial line requirements:

Continuous monitoring: Invasive arterial line (radial or femoral) mandatory
Waveform interpretation: Critical for timing adjustment
Pressure trigger: Used if ECG signal poor (arrhythmias, poor ECG quality) [6,20]

ECG synchronization:

Trigger: R-wave detection (most reliable)
Artifact rejection: Pacemaker spikes, electrical interference
Arrhythmias: Atrial fibrillation, premature beats may affect timing; consider pressure trigger [6,20]

ACT monitoring:

Target: 180-200 seconds (for heparin infusion)
Frequency: Check every 4-6 hours (q4-6h)
Bolus: 500-1000 U heparin IV if ACT below 180 sec [21]

Limb perfusion monitoring:

Doppler ultrasound: Assess pedal pulses hourly
Compartment pressure: If clinical suspicion of compartment syndrome
Capillary refill: Delay greater than 2 seconds concerning for ischemia [9,10]

Indications

Cardiogenic Shock

Acute Myocardial Infarction-Related Cardiogenic Shock:

Historical indication: Previously standard of care (pre-IABP-SHOCK II)
Exception: Mechanical complications (VSD, papillary muscle rupture, free wall rupture) where IABP still has role [1,2,14]

Non-AMI Cardiogenic Shock:

Acute decompensated heart failure: May provide temporary stabilization
Myocarditis: Adjunctive support (often combined with VA-ECMO)
Post-cardiotomy shock: Useful adjunct in cardiac surgery patients
Evidence: Limited, case series suggest benefit in selected patients [27,28]

IABP-SHOCK II trial details:

Design: Multicenter RCT, 600 patients, AMI-related cardiogenic shock
Intervention: IABP + optimal medical therapy vs optimal medical therapy alone
Primary endpoint: 30-day all-cause mortality
Results: 39.7% mortality (IABP) vs 41.3% (control), p=0.69 (NO difference)
Secondary endpoints: No difference in stroke, bleeding, peripheral ischemia, sepsis
Implication: IABP no longer recommended for AMI-related cardiogenic shock [1,2]

SHOCK trial context:

1999 SHOCK trial: Early revascularization + IABP improved mortality in AMI-related cardiogenic shock
Interpretation: Benefit attributed to early revascularization, NOT IABP
IABP-SHOCK II: Directly tested IABP in modern era (with early revascularization) - showed no benefit [1,29]

Acute Mitral Regurgitation

Papillary Muscle Rupture (Post-MI):

Pathophysiology: Posterior papillary muscle rupture more common (right coronary artery territory)
Hemodynamics: Severe acute MR → volume overload → pulmonary edema → cardiogenic shock
IABP benefit: Afterload reduction reduces regurgitant fraction, improves forward flow
Timing: Bridge to urgent surgical repair or transcatheter valve intervention [30,31]

Ischemic MR (Functional):

Mechanism: Papillary muscle dysfunction from ischemia → annular dilation → MR
Severity: Variable, may improve with revascularization
IABP role: Temporary support, afterload reduction until definitive therapy (PCI or surgery) [30]

Acute MR without papillary rupture:

Etiology: Infective endocarditis, traumatic chordal rupture, prosthetic valve dysfunction
IABP indication: Stabilization before definitive surgical intervention [30,31]

High-Risk Percutaneous Coronary Intervention

Definition of high-risk PCI:

Anatomical: Left main disease, multivessel disease, bifurcation lesions, chronic total occlusions
Clinical: LVEF below 35%, extensive prior MI, diabetes, CKD
Procedural: Use of rotational atherectomy, multiple stents, complex techniques [32,33]

IABP as prophylactic support:

Rationale: Hemodynamic support during prolonged or complex PCI
Timing: Inserted prior to PCI, removed after procedure (or continued if hemodynamic instability)
Evidence: Mixed - some trials show benefit, others no mortality benefit
BCIS-1 trial: 301 patients, elective high-risk PCI, IABP vs no IABP, NO difference in long-term mortality [32]

Alternative devices:

Impella: Higher support (up to 3.5-5.0 L/min), percutaneous LV unloading
TandemHeart: LA-to-aortic bypass, higher support than IABP
VA-ECMO: Cardiopulmonary support for very high-risk cases [15,16]

Bridge to Advanced Therapies

Bridge to Ventricular Assist Device (VAD):

Purpose: Temporary stabilization while LVAD evaluation and implantation planned
Duration: Typically 24-72 hours
Indications: Interim stabilization in refractory cardiogenic shock
Outcomes: Improved survival to LVAD implantation compared to medical therapy alone [17,18]

Bridge to Heart Transplant:

Purpose: Maintains patient stability while awaiting donor heart
Duration: May be days to weeks (longer than typical IABP use)
Limitations: IABP provides limited support; may require transition to VA-ECMO for prolonged bridging [17,18]

Bridge to Decision:

Purpose: Temporary support while determining reversibility of cardiac dysfunction
Duration: 24-48 hours typically
Scenarios: Myocarditis (potentially reversible), post-cardiotomy shock (waiting for recovery), acute MI with uncertain revascularization benefit [27,28]

Other Indications

Ventricular Septal Defect (Post-MI):

Etiology: Septal rupture following MI (typically 3-5 days post-MI)
Hemodynamics: Left-to-right shunt → pulmonary overcirculation → right ventricular failure
IABP role: Reduces LV afterload, reduces shunt fraction, improves hemodynamics
Definitive therapy: Surgical repair or transcatheter closure [30,31]

Cardiac Surgery Support:

Weaning from CPB: Difficulty weaning from cardiopulmonary bypass
Low cardiac output state: Post-cardiotomy shock (ischemia-reperfusion injury, myocardial stunning)
Evidence: Reduces mortality in high-risk cardiac surgery patients [28,34]

Septic Cardiomyopathy:

Etiology: Cytokine-mediated myocardial depression
IABP role: May provide temporary support while treating underlying sepsis
Evidence: Limited, case reports only; generally VA-ECMO preferred for severe septic cardiomyopathy [35]

Contraindications

Absolute Contraindications

Aortic Regurgitation (Moderate to Severe):

Mechanism: Balloon deflates during diastole when regurgitant flow occurs
Hemodynamic effect: Loss of diastolic backflow resistance → worsened volume overload → pulmonary edema
Severity: Moderate or severe AR (any degree of AR considered relative by some guidelines)
Evidence: Case reports of rapid deterioration with IABP in AR [7,8]

Aortic Dissection:

Type A dissection: Absolute contraindication (involves ascending aorta, risk of rupture into pericardium)
Type B dissection: Relative contraindication (may be considered in selected cases under surgical oversight)
Risk: Balloon may propagate dissection, cause rupture, or occlude true lumen
Imaging: Must rule out with CT aortogram or TEE before insertion [7,8]

Severe Aortic Aneurysm/Disease:

Thoracic aortic aneurysm: greater than 5.5 cm (risk of rupture from balloon motion)
Atherosclerotic aortic disease: Severe, protruding atheroma (embolization risk)
Aortic mural thrombus: Risk of embolization with balloon motion
Imaging: CT aortogram or TEE required to assess aortic pathology [7,8]

Relative Contraindications

Coagulopathy:

INR greater than 1.5: Increased bleeding risk at insertion site, intracranial hemorrhage risk
Thrombocytopenia: Platelets below 50,000/µL (increased bleeding, thrombosis risk from platelet consumption)
Active bleeding: GI bleeding, intracranial hemorrhage, surgical bleeding
Management: Correct coagulopathy (FFP, platelets) before insertion; monitor ACT during IABP therapy [21]

Severe Peripheral Artery Disease:

Iliac artery stenosis: Difficulty advancing catheter, risk of limb ischemia
Femoral artery disease: Small caliber, calcification, prior stents
Alternatives: Subclavian approach (rare), percutaneous LV support (Impella), VA-ECMO [7,9]

Sepsis:

Risk of infection: Balloon catheter as foreign body, potential for septic emboli
Bleeding risk: Coagulopathy from sepsis
Hemodynamic profile: Sepsis typically causes distributive shock (warm shock), not cardiogenic shock
Alternative therapies: Vasopressors, source control, antibiotics [35]

Severe Aortic Stenosis:

Mechanism: Fixed outflow obstruction, IABP reduces coronary perfusion pressure (diastolic augmentation less effective)
Hemodynamics: Fixed gradient across aortic valve, afterload reduction less beneficial
Alternatives: Balloon aortic valvuloplasty, TAVR, medical therapy [23]

Arrhythmias:

Atrial fibrillation: Irregular rhythm affects timing; may require pressure trigger instead of ECG trigger
Ventricular tachycardia/arrhythmias: Poor ECG synchronization, may cause ineffective counterpulsation
Management: Consider rate control, electrical cardioversion, or alternative therapies [6,20]

Procedure: IABP Insertion

Pre-Procedural Preparation

Patient selection and consent:

Indication verification: Confirm appropriate indication (cardiogenic shock, acute MR, high-risk PCI)
Contraindication assessment: Rule out aortic dissection (CT/TEE), assess AR (echocardiogram), evaluate peripheral vascular disease
Informed consent: Discuss risks (limb ischemia 1-5%, stroke 1-3%, bleeding, aortic injury) and benefits [7,9]

Laboratory assessment:

Coagulation profile: INR, PTT, platelet count
CBC: Hemoglobin, hematocrit, platelets
Renal function: Creatinine, BUN (contrast for imaging if needed)
ECG: Baseline rhythm, ischemia, arrhythmias [21]

Imaging:

Chest X-ray: Baseline for balloon position verification post-insertion
Echocardiogram: Assess LV function, AR severity, VSD, papillary muscle rupture
CT aortogram or TEE: If suspicion of aortic dissection or aneurysm (essential to rule out) [7,8]

Equipment preparation:

IABP catheter selection: Based on patient height (30, 34, 40 cc balloon volume)
Catheter size: 7.5-8.0 Fr (smaller size reduces limb ischemia risk)
Console check: Helium supply, ECG cables, pressure tubing
Arterial line setup: For continuous monitoring and timing [20]

Insertion Technique

Positioning and draping:

Patient position: Supine, slight Trendelenburg (to facilitate femoral artery access)
Monitoring: Continuous ECG, invasive arterial line, pulse oximetry, capnography
Draping: Sterile drapes, full barrier precautions [20]

Access site selection:

Primary site: Common femoral artery (preferred - largest diameter)
Side selection: Contralateral to any arterial sheaths (if patient has existing arterial access)
Assessment: Palpate femoral pulse, assess for peripheral pulses (dorsalis pedis, posterior tibial) [20]

Seldinger technique (most common):

Local anesthesia: Lidocaine 1% subcutaneously and around femoral artery
Needle puncture: 18G needle at 45° angle targeting femoral artery (pulsatile backflow)
Guidewire insertion: J-tip guidewire advanced, check for free advancement (no resistance)
Needle removal: Remove needle over guidewire
Skin nick: Small incision with #11 blade scalpel
Dilator insertion: Dilator over guidewire (if using sheathless technique, skip sheath)
Balloon catheter insertion: IABP catheter advanced over guidewire to correct position
Guidewire removal: Remove guidewire after balloon positioned correctly
Secure catheter: Suture to skin, apply sterile dressing [20]

Sheathless vs sheathed technique:

Sheathless: Balloon catheter inserted directly (smaller effective diameter, less limb ischemia) - PREFERRED
Sheathed: Sheath inserted first, then balloon catheter (easier, but larger diameter increases limb ischemia risk) [20]

Balloon positioning:

Target position: 1-2 cm distal to left subclavian artery (ensures balloon is in descending thoracic aorta)
Avoid: Above left subclavian artery (risk of occluding carotid/subclavian vessels), above renal arteries (risk of renal hypoperfusion)
Verification: Chest X-ray (balloon tip should be at T4-T5 level, 1-2 cm below aortic knob) [20]

Post-Insertion Care

Hemodynamic monitoring:

Arterial waveform: Continuous monitoring for timing assessment
Vital signs: HR, BP, SpO2, temperature
IABP console: Verify inflation/deflation timing, assist ratio, helium status
ACT: Check every 4-6 hours (target 180-200 sec) [6,21]

Limb perfusion monitoring:

Pedal pulses: Palpate or use Doppler every hour
Capillary refill: Assess distal perfusion
Skin changes: Pallor, cyanosis, coolness
Compartment pressure: If clinical suspicion of compartment syndrome (pain, swelling, tense compartments) [9,10]

Anticoagulation:

Heparin infusion: 500-1000 U/hr (titrate to ACT 180-200 sec)
Loading dose: Optional (5000 U IV bolus if no contraindication)
Bleeding monitoring: Check insertion site, urine output, hemoglobin [21]

CXR verification:

Timing: Immediate post-insertion CXR
Position: Balloon tip should be at T4-T5 level
Adjustment: If too high (risk of great vessel occlusion) or too low (risk of renal artery occlusion) [20]

Complication surveillance:

Bleeding: Insertion site, hematuria, GI bleeding, intracranial hemorrhage
Limb ischemia: Decreased pedal pulses, cool extremity, pain, compartment syndrome
Neurologic changes: Stroke (embolic or hypoperfusion)
Hemolysis: Dark urine, decreased hemoglobin, elevated LDH [9-13]

Complications

Limb Ischemia

Incidence and risk factors:

Overall incidence: 1-5% (most common complication)
Risk factors: Female gender, diabetes, peripheral vascular disease, small catheter diameter, prolonged use greater than 72 hours, smoking [9,10]

Pathophysiology:

Mechanism: IABP catheter occludes femoral artery lumen (especially with sheathed technique)
Emboli: Atheroembolism from catheter manipulation
Thrombosis: In situ thrombosis around catheter, heparin-induced thrombocytopenia (rare)
Compartment syndrome: Prolonged ischemia → increased compartment pressure → tissue necrosis [9,10]

Clinical presentation:

Early signs: Decreased pedal pulse (Doppler), cool extremity, pallor, pain
Late signs: Cyanosis, sensory loss, motor weakness, compartment syndrome, tissue necrosis
Timing: Can occur immediately or develop gradually over days [9,10]

Diagnosis:

Clinical: Assess pedal pulses, capillary refill, skin temperature
Doppler ultrasound: Evaluate femoral artery flow, detect thrombosis
Ankle-brachial index (ABI): below 0.9 suggests arterial occlusion
Compartment pressure: If suspicion of compartment syndrome (greater than 30 mmHg indicates compartment syndrome) [9,10]

Prevention:

Sheathless technique: Reduces effective catheter diameter
Appropriate sizing: Use smallest catheter that provides adequate support (30-40 cc balloon)
Limb monitoring: Hourly assessment of pedal pulses and distal perfusion
Early detection: Prompt action if any signs of ischemia develop [9,10]

Management:

Mild ischemia: Reposition catheter, consider removal if hemodynamically stable
Moderate ischemia: Remove IABP catheter, consider alternative support (VA-ECMO, Impella)
Severe ischemia: Emergent vascular surgery consultation for embolectomy or fasciotomy
Amputation: Indicated for tissue necrosis, gangrene [9,10]

Aortic Injury

Incidence and types:

Overall incidence: 0.5-1% (rare but potentially catastrophic)
Types: Aortic dissection, aortic perforation/rupture, aortic injury (intimal tear) [12]

Risk factors:

Atherosclerotic aorta: Severe aortic plaque, calcification
Aortic aneurysm: Undiagnosed thoracic or abdominal aortic aneurysm
Inappropriate technique: Forceful catheter advancement, poor positioning
Prolonged use: Balloon motion causing endothelial injury [12]

Clinical presentation:

Aortic dissection: Sudden severe chest/back pain (tearing sensation), hypotension, pulse deficits, widened mediastinum on CXR
Aortic perforation: Sudden cardiovascular collapse, cardiac tamponade (if ascending aorta), hemothorax (if descending aorta)
Intimal injury: Often asymptomatic, may cause embolic phenomena [12]

Diagnosis:

CXR: Widened mediastinum, apical cap, pleural effusion (if perforation)
CT aortogram: Gold standard for diagnosis of aortic dissection or perforation
TEE: Useful alternative if CT unavailable, especially for ascending aorta [12]

Prevention:

Screening: CT aortogram or TEE in high-risk patients (known aortic disease, prior dissection)
Technique: Gentle catheter advancement, verify position with fluoroscopy/CXR
Avoid: IABP in known aortic dissection or severe aortic aneurysm [12]

Management:

Immediate IABP removal: Remove catheter immediately if aortic injury suspected
Emergent imaging: CT aortogram to confirm diagnosis
Consultation: Cardiovascular surgery for definitive management (surgical repair, endovascular stenting)
Supportive care: Blood pressure control, analgesia, hemodynamic support [12]

Stroke

Incidence and mechanisms:

Overall incidence: 1-3%
Mechanisms:
- "Atheroembolism: Aortic plaque disruption by catheter manipulation or balloon motion"
- "Hypoperfusion: Inadequate cerebral perfusion if IABP fails or during prolonged hypotension"
- "Thromboembolism: In situ thrombosis or heparin-induced thrombocytopenia (rare) [11]"

Risk factors:

Aortic atherosclerosis: Mobile aortic plaque, atheroma burden
Prolonged use: greater than 7 days increased risk
Hypotension: Prolonged periods of low MAP (below 65 mmHg)
Coagulopathy: Thrombocytopenia, heparin-induced thrombocytopenia [11]

Clinical presentation:

Ischemic stroke: Focal neurologic deficits (hemiparesis, aphasia, visual field defects)
Hemorrhagic stroke: Headache, decreased consciousness, focal signs
Timing: Can occur immediately after insertion or develop days later [11]

Diagnosis:

CT head: Rule out hemorrhage
MRI brain: Gold standard for ischemic stroke detection (diffusion-weighted imaging)
Neurologic assessment: NIH Stroke Scale (NIHSS) [11]

Prevention:

Screening: Identify high-risk aortic atherosclerosis (TEE prior to insertion)
Gentle technique: Minimize catheter manipulation, avoid forceful advancement
Anticoagulation: Maintain ACT 180-200 sec (heparin infusion)
Blood pressure control: Maintain MAP greater than 65 mmHg [11,21]

Management:

Immediate IABP removal: Consider removal if stroke suspected (after neurologic imaging)
Neurology consultation: For acute stroke management (thrombolysis, thrombectomy if indicated)
Supportive care: Airway protection, blood pressure management, rehabilitation [11]

Hemolysis and Hematologic Complications

Hemolysis:

Incidence: 5-10% (usually mild, severe hemolysis rare)
Mechanism: Mechanical red blood cell destruction from balloon motion
Clinical presentation: Dark urine (hemoglobinuria), decreased hemoglobin, elevated LDH, elevated indirect bilirubin [13]

Thrombocytopenia:

Incidence: 10-20%
Mechanism: Platelet activation and consumption, heparin-induced thrombocytopenia (HIT) rare
Clinical presentation: Decreasing platelet count, bleeding complications [13]

Management:

Monitoring: CBC daily, LDH, bilirubin
Hemolysis: Usually self-limited, consider balloon exchange if severe hemolysis persists
Thrombocytopenia: Maintain platelets greater than 50,000/µL, monitor for HIT if platelet drop greater than 50% [13]

Bleeding Complications

Insertion site bleeding:

Incidence: 5-10%
Risk factors: Coagulopathy, thrombocytopenia, large sheath size, aggressive anticoagulation [21]

Non-insertion site bleeding:

GI bleeding: 2-3%
Intracranial hemorrhage: 1-2% (catastrophic)
Retroperitoneal hemorrhage: 1-2% (potentially life-threatening) [21]

Management:

Anticoagulation adjustment: Reduce or hold heparin infusion
Local measures: Pressure at insertion site, protamine if needed
Blood product support: FFP, platelets, PRBC as indicated
IABP removal: Consider early removal if severe bleeding [21]

Infection

Catheter-related infection:

Incidence: 1-3%
Pathogens: Staphylococcus aureus (most common), Gram-negative organisms
Risk factors: Prolonged use greater than 7 days, diabetes, immunosuppression [22]

Bacteremia:

Incidence: 1-2%
Complications: Sepsis, endocarditis, metastatic infection [22]

Management:

Prophylactic antibiotics: Not routinely recommended
Blood cultures: If fever or leukocytosis develops
IABP removal: Remove catheter if infection suspected, send tip for culture
Antibiotic therapy: Directed at blood culture results [22]

Balloon Malfunction

Types of malfunction:

Balloon rupture: Helium leak, loss of counterpulsation
Console malfunction: Timing errors, pressure trigger failure
Catheter kinking: Impaired helium flow, reduced augmentation [20]

Management:

Balloon rupture: Immediate removal, risk of helium embolism (rare but potentially fatal)
Console malfunction: Troubleshoot with manufacturer support, consider balloon exchange
Catheter kinking: Reposition catheter, consider exchange if unable to correct [20]

Evidence and Clinical Trials

IABP-SHOCK II Trial

Trial design:

Type: Multicenter, prospective, randomized, open-label trial
Population: 600 patients with acute myocardial infarction-related cardiogenic shock
Inclusion criteria: AMI below 48 hours, cardiogenic shock (SBP below 90 mmHg or requiring vasopressors), planned early revascularization
Intervention: IABP insertion + optimal medical therapy vs optimal medical therapy alone
Primary endpoint: 30-day all-cause mortality [1,2]

Results:

30-day mortality: 39.7% (IABP group) vs 41.3% (control group), p=0.69 (NO difference)
12-month mortality: 52.0% (IABP) vs 51.6% (control), p=0.98 (NO difference)
Secondary endpoints: No significant differences in stroke, bleeding, peripheral ischemia, sepsis, time to hemodynamic stabilization, ICU length of stay [1,2]

Key findings:

No mortality benefit: IABP did NOT improve survival in AMI-related cardiogenic shock
No complications benefit: IABP did NOT reduce complications compared to medical therapy alone
Practice-changing: Led to guideline downgrading of IABP for AMI-related cardiogenic shock [1,2]

Subgroup analyses:

Age: No benefit in any age group (below 60, 60-75, greater than 75 years)
Time to revascularization: No benefit with early vs late revascularization
Baseline severity: No benefit based on LVEF, lactate level, or severity of shock
Conclusion: No subgroup benefited from IABP [1]

Impact on guidelines:

ESC 2017/2020 guidelines: Class III recommendation (harmful/no benefit) for IABP in AMI-related cardiogenic shock
AHA/ACC guidelines: Class IIb recommendation (may be considered) - less restrictive than ESC
Regional variation: Europe/North America reduced IABP use significantly after trial; Asia-Pacific maintained higher utilization [14,24]

Limitations:

Early revascularization: 95% underwent early revascularization (may confound - benefit attributed to revascularization, not IABP)
Exclusions: Mechanical complications (VSD, papillary muscle rupture) excluded
Sample size: 600 patients may be underpowered for subgroup analyses [1,2]

Other Key Trials

SHOCK Trial (1999):

Design: Early revascularization vs initial medical stabilization in AMI-related cardiogenic shock
IABP use: 86% of patients received IABP (standard of care at time)
Results: Early revascularization reduced 6-month mortality (50% vs 63%, p=0.03)
Interpretation: Benefit attributed to early revascularization, NOT IABP [29]

TACTICS Trial (2005):

Design: IABP vs intra-aortic axial flow pump (Impella) in high-risk PCI
Results: No significant difference in major adverse cardiac events (MACE)
Conclusion: Similar efficacy for procedural support [15]

PROTECT II Trial (2012):

Design: Impella vs IABP in high-risk PCI
Results: Impella showed trend toward improved 30-day outcomes (not statistically significant)
Conclusion: Impella may provide superior hemodynamic support, but larger trials needed [15]

BCIS-1 Trial (2013):

Design: Elective IABP vs no IABP in high-risk PCI
Population: 301 patients, elective high-risk PCI (LVEF below 30%)
Results: No difference in long-term mortality (13% vs 15%, p=0.61)
Complications: IABP group had higher bleeding rates [32]

Meta-analyses:

Sjauw et al. (2009, JAMA): Meta-analysis of 7 randomized trials (n=972) - NO mortality benefit for IABP in cardiogenic shock
Unverzagt et al. (2015, Heart): Meta-analysis including IABP-SHOCK II - confirmed NO mortality benefit
Conclusion: Consistent evidence across trials that IABP does NOT improve mortality in cardiogenic shock [24,36]

Current Evidence Summary

Evidence-based indications:

Mechanical complications of MI: VSD, papillary muscle rupture - benefit suggested (limited RCT data, observational studies)
High-risk PCI: Prophylactic use controversial; no mortality benefit in RCTs (BCIS-1, TACTICS)
Bridge to VAD/transplant: Observational data support temporary stabilization role
Post-cardiotomy shock: Some benefit in selected cardiac surgery patients [17,28,30]

Evidence-based contraindications:

AMI-related cardiogenic shock: Class III recommendation based on IABP-SHOCK II (NO benefit)
Aortic regurgitation: Absolute contraindication (physiological rationale, case reports)
Aortic dissection: Absolute contraindication (risk of propagation) [1,7,14]

Comparison with Other Mechanical Circulatory Support Devices

IABP vs VA-ECMO

IABP characteristics:

Support level: 0.5-1.0 L/min (modest increase)
Mechanism: Counterpulsation (diastolic augmentation, afterload reduction)
Insertion: Percutaneous, 7.5-8.0 Fr catheter
Complications: Lower bleeding risk, limb ischemia 1-5%
Limitations: Limited support, NOT sufficient for severe cardiogenic shock [15,16]

VA-ECMO characteristics:

Support level: 3-5 L/min (cardiopulmonary support)
Mechanism: Venous to arterial bypass (full cardiac and respiratory support)
Insertion: Percutaneous or surgical, larger cannulas (15-19 Fr arterial, 19-23 Fr venous)
Complications: Higher bleeding risk, limb ischemia up to 10-15%
Advantages: Higher support, can support cardiac and respiratory failure [15,16]

Clinical decision-making:

IABP preferred: Mild cardiogenic shock, high-risk PCI, bridge to VAD/transplant (短期支持)
VA-ECMO preferred: Severe cardiogenic shock (CI below 1.8 L/min/m²), refractory to medical therapy and IABP, cardiac arrest (ECPR) [15,16]

IABP vs Impella

IABP characteristics:

Support level: 0.5-1.0 L/min
Mechanism: Counterpulsation (diastolic augmentation, afterload reduction)
Cannulation: Femoral artery, 7.5-8.0 Fr
LV unloading: Indirect (afterload reduction)
Cost: Lower (device cost ~$5,000-$10,000) [15,16]

Impella characteristics:

Support level: 2.5-5.0 L/min (Impella 2.5 = 2.5 L/min, Impella CP = 3.5-4.0 L/min, Impella 5.0 = 5.0 L/min)
Mechanism: Transvalvular axial flow pump (direct LV unloading)
Cannulation: Femoral artery, 13-21 Fr (larger than IABP)
LV unloading: Direct (pumps blood from LV to aorta)
Cost: Higher (device cost ~$20,000-$50,000) [15,16]

Clinical evidence:

PROTECT II trial: Impella trend toward better 30-day outcomes vs IABP in high-risk PCI (not statistically significant)
TACTICS trial: No significant difference between Impella and IABP in high-risk PCI
Current practice: Impella preferred for severe LV failure requiring higher support [15]

IABP vs TandemHeart

IABP characteristics:

Support level: 0.5-1.0 L/min
Mechanism: Counterpulsation
Insertion: Percutaneous, 7.5-8.0 Fr
Complexity: Simple insertion, minimal operator expertise [15,16]

TandemHeart characteristics:

Support level: 3-5 L/min
Mechanism: LA-to-aortic bypass (transseptal puncture)
Insertion: Percutaneous transseptal puncture (LA cannulation) + femoral artery outflow
Complexity: Complex insertion, requires expertise (transseptal puncture)
Complications: Transseptal complications, arrhythmias, bleeding [15,16]

Clinical role:

TandemHeart: Used when high-level support needed but VA-ECMO not available
IABP: Simpler alternative when lower support needed

Device Selection Algorithm

Step 1: Assess severity of shock

Mild (CI 1.8-2.2 L/min/m²): IABP or Impella 2.5
Moderate (CI 1.5-1.8 L/min/m²): Impella CP or TandemHeart
Severe (CI below 1.5 L/min/m²): VA-ECMO or TandemHeart [15,16]

Step 2: Assess LV vs biventricular failure

Isolated LV failure: IABP, Impella, TandemHeart
Biventricular failure: VA-ECMO (or BiVAD) [15,16]

Step 3: Assess concomitant respiratory failure

Respiratory failure present: VA-ECMO (provides respiratory support)
No respiratory failure: IABP, Impella, TandemHeart [15,16]

Step 4: Consider contraindications and logistics

Peripheral vascular disease: IABP preferred (smaller catheter)
Aortic regurgitation: Avoid IABP, consider VA-ECMO
Cost and availability: IABP most widely available, lowest cost [15,16]

Weaning and Removal

Weaning Protocol

Weaning criteria:

Hemodynamic stability: SBP greater than 90 mmHg without vasopressors or on low-dose vasopressors (norepinephrine below 0.05 µg/kg/min)
Cardiac output: CI greater than 2.0 L/min/m²
Lactate: below 2.0 mmol/L (or trending down)
No ongoing ischemia: No ST changes, no arrhythmias
Adequate urine output: greater than 0.5 mL/kg/hr [6,19]

Weaning protocol (standard):

Full support (1:1): Continue until hemodynamically stable for 24-48 hours
Partial support (1:2): Assist ratio 1:2 for 6-12 hours, monitor for hemodynamic deterioration
Advanced weaning (1:3): Assist ratio 1:3 for 6-12 hours (if tolerated)
Trial off (1:4): Assist ratio 1:4 for 30-60 minutes, monitor for deterioration
Removal: If stable during 1:4 trial, remove IABP [6,19]

Hemodynamic deterioration during weaning:

Definitions: HR increase greater than 20 beats/min, SBP decrease greater than 20 mmHg, CI decrease greater than 0.5 L/min/m², lactate increase greater than 1.0 mmol/L
Management: Return to previous assist ratio, optimize medical therapy (inotropes, diuretics), delay weaning
Alternative therapy: Consider advanced MCS (VA-ECMO, Impella) if unable to wean to 1:1 [6,19]

Removal Technique

Pre-removal preparation:

Consent: Informed consent for removal (risks: bleeding, hematoma, pseudoaneurysm)
Anticoagulation: Hold heparin infusion 1-2 hours before removal
Equipment: Suture removal kit, sterile dressing, pressure device [20]

Removal technique (sheathless):

Discontinue heparin: Hold infusion 1-2 hours prior
Prepare patient: Supine, slight Trendelenburg position
Remove sutures: Cut and remove anchoring sutures
Remove catheter: Slowly withdraw IABP catheter over 1-2 minutes
Apply manual pressure: Continuous pressure at femoral artery site for 20-30 minutes (or until hemostasis)
Apply sterile dressing: Occlusive dressing
Monitor distal perfusion: Assess pedal pulses, capillary refill [20]

Removal technique (sheathed):

Remove IABP catheter: Withdraw balloon catheter, leave sheath in place
Allow hemostasis: Wait 5-10 minutes for local hemostasis
Remove sheath: Slowly withdraw sheath
Apply manual pressure: 20-30 minutes (longer if larger sheath)
Apply sterile dressing
Monitor distal perfusion [20]

Post-Removal Care

Monitoring:

Vital signs: HR, BP, SpO2 for 4-6 hours
Insertion site: Check for bleeding, hematoma, pseudoaneurysm every 30 minutes for 2 hours, then hourly for 4 hours
Distal perfusion: Assess pedal pulses, capillary refill, skin color and temperature [20]

Complications:

Bleeding/hematoma: Manage with pressure, transfusion if needed
Pseudoaneurysm: Ultrasound-guided thrombin injection or surgical repair
Arteriovenous fistula: Ultrasound evaluation, may require surgical repair
Limb ischemia: Assess Doppler, vascular surgery consultation [9,10,20]

Special Considerations

IABP in Pregnancy

Indications:

Peripartum cardiomyopathy: Bridge to recovery or transplant
Acute MI in pregnancy: Cardiogenic shock from AMI
Acute MR: Postpartum or antepartum cardiogenic shock [37]

Considerations:

Fetal monitoring: Continuous fetal heart rate monitoring
Radiation exposure: Minimize fluoroscopy during insertion (use ultrasound guidance if possible)
Delivery timing: Coordinate with obstetrics and cardiology for delivery planning
Postpartum: May require continuation of IABP postpartum for stabilization [37]

IABP in Elderly Patients

Considerations:

Frailty: Assess frailty status, comorbidities, quality of life
Bleeding risk: Higher risk of bleeding complications (vascular fragility, polypharmacy)
Prognosis: Consider goals of care, advance directives
Outcomes: Higher mortality, but selected elderly patients may benefit [24,26]

IABP in Renal Failure

Considerations:

Contrast load: Minimize contrast for imaging (use non-contrast imaging if possible)
Anticoagulation: Adjust heparin dosing based on renal function (heparin cleared by liver, but consider HIT risk)
Bleeding risk: Uremic platelet dysfunction
Dialysis: May need CRRT or IHD during IABP therapy (coordinate timing) [9,21]

IABP in Coagulopathy

Considerations:

Correction: Transfuse platelets (greater than 50,000/µL), FFP, vitamin K before insertion
Monitoring: Check INR, PTT, platelets every 4-6 hours
Anticoagulation: Consider lower heparin infusion rate or no heparin if high bleeding risk
Bleeding management: Have blood products readily available [21]

Nursing Considerations

Monitoring Requirements

Continuous monitoring:

IABP console: Helium status, assist ratio, timing (ECG vs pressure trigger), augmented diastolic pressure
Arterial waveform: Continuous arterial line for timing assessment, blood pressure monitoring
ECG: Continuous rhythm monitoring, detect arrhythmias affecting timing
Vital signs: HR, BP, SpO2, temperature [6,20]

Hourly assessments:

Pedal pulses: Palpate or use Doppler to assess distal perfusion
Capillary refill: Delay greater than 2 seconds concerning for limb ischemia
Skin assessment: Color, temperature, sensation of affected extremity
Insertion site: Check for bleeding, infection signs [9,10]

Every 4-6 hours:

ACT: Check ACT level (target 180-200 sec), adjust heparin infusion as needed
CXR: Verify balloon position daily (T4-T5 level, 1-2 cm below aortic knob)
Labs: CBC, coagulation profile, basic metabolic panel [21]

Alarm Management

Common IABP alarms:

Helium alarm: Helium supply low or empty - replace helium cylinder
ECG trigger alarm: Poor ECG signal, arrhythmia - check leads, consider pressure trigger
Pressure trigger alarm: Poor arterial waveform - check arterial line, flush tubing
Catheter alarm: Catheter malposition, kinking - verify position, reposition if needed [20]

Management:

Do NOT ignore alarms: Investigate and address cause immediately
Standby mode: Use standby mode while troubleshooting (balloon will not inflate)
Document: Alarm, troubleshooting steps, resolution [20]

Patient Education

Pre-insertion education:

Procedure explanation: Describe IABP, catheter insertion, expected duration
Risks and benefits: Limb ischemia, bleeding, stroke; improved hemodynamics
Activity restrictions: Bed rest, limited hip flexion (below 30°) on affected side [20]

During IABP therapy:

Bed rest: Remain in bed, avoid turning on affected side without assistance
Notify nurse: If experiencing pain, numbness, tingling in affected extremity
Femoral site: Keep dry, avoid touching [20]

Post-removal education:

Site care: Keep insertion site clean and dry, monitor for bleeding or infection
Activity: Gradual increase in activity as tolerated
Follow-up: Cardiology follow-up for underlying condition [20]

Pharmacologic Considerations

Anticoagulation During IABP Therapy

Heparin protocol:

Bolus: Optional (5000 U IV if no contraindication)
Infusion: 500-1000 U/hr (titrate to ACT 180-200 sec)
Monitoring: Check ACT every 4-6 hours (q4-6h)
Adjustment: Increase infusion by 100-200 U/hr if ACT below 180 sec; decrease by 100-200 U/hr if ACT greater than 200 sec [21]

Alternative anticoagulation:

Bivalirudin: Alternative if heparin-induced thrombocytopenia (HIT) suspected
Direct oral anticoagulants (DOACs): NOT recommended during IABP therapy
No anticoagulation: Consider in high bleeding risk (but increased thrombosis risk) [21]

Hemodynamic Adjuncts

Inotropes (during IABP therapy):

Dobutamine: 2.5-10 µg/kg/min - beta-1 agonist, increases myocardial contractility
Milrinone: 0.375-0.75 µg/kg/min loading, then 0.375-0.75 µg/kg/min infusion - phosphodiesterase inhibitor, vasodilatory effect (use with caution in hypotension)
Epinephrine: 0.01-0.1 µg/kg/min - potent inotrope and vasopressor, use in severe shock [35]

Vasopressors (during IABP therapy):

Norepinephrine: 0.01-0.3 µg/kg/min - alpha-1 agonist, increases SVR, used for persistent hypotension
Vasopressin: 0.03 U/min - V1 receptor agonist, used for refractory hypotension
Phenylephrine: 20-200 µg/min - pure alpha-1 agonist, increases SVR (use with caution, increases afterload) [35]

Diuretics:

Furosemide: 20-80 mg IV q6-12h - for volume overload, pulmonary edema
Torsemide: 10-40 mg IV q24h - alternative diuretic, longer duration of action [35]

Australian Context

Availability and Access

Hospital tier availability:

Tertiary ICUs: IABP widely available (major teaching hospitals, cardiothoracic surgery centers)
Regional ICUs: Limited availability, transfer to tertiary center required
Remote hospitals: No IABP availability, early retrieval indicated [24]

Retrieval considerations:

RFDS (Royal Flying Doctor Service): Can transport patients with IABP in situ (specialized retrieval teams)
State-based retrieval services: NETS (NSW), PETS (QLD), PIPER (VIC), MedSTAR (SA/NT)
Interhospital transfer: May require specialized retrieval team, ensure helium supply, console battery, spare catheters available [24]

Guidelines and Protocols

Australian and New Zealand Intensive Care Society (ANZICS):

Guidelines: ANZICS Adult Patient Database (APD) guidelines for mechanical circulatory support
Position statements: Available on ANZICS website for IABP and other MCS devices [24]

Cardiac Society of Australia and New Zealand (CSANZ):

Guidelines: CSANZ guidelines for acute coronary syndromes and cardiogenic shock
Recommendations: IABP Class III for AMI-related cardiogenic shock (consistent with ESC) [14]

Equipment and Cost

Device availability:

Brands: Maquet (now Getinge), Datascope (now Arrow/Telus)
Cost: IABP catheter $5,000-$10,000 AUD; console $50,000-$100,000 AUD
Funding: Public hospitals via state health departments, private hospitals via health insurance [24]

Indigenous Health Considerations

Higher burden of cardiovascular disease:

Aboriginal and Torres Strait Islander: Higher rates of AMI, cardiogenic shock at younger age
Māori: Higher cardiovascular disease burden compared to non-Māori
Rural and remote: Geographic barriers to tertiary care with IABP capability [24]

Cultural safety:

Communication: Clear explanation of IABP therapy in culturally appropriate language
Family involvement: Involve family/whānau in decision-making, consider cultural protocols
Traditional healing: Respect and integrate traditional healing practices where appropriate

Geographic barriers:

Remote areas: Delayed access to tertiary care with IABP, consider early retrieval
RFDS coordination: Early liaison with retrieval services for patients with cardiogenic shock
Telemedicine: Use telehealth for consultation with tertiary ICU while managing patient locally [24]

Practical Tips and Pearls

Procedural Pearls

Insertion tips:

Ultrasound guidance: Use ultrasound for femoral artery puncture (reduces complications)
Sheathless technique: Preferred to reduce limb ischemia risk
Appropriate sizing: Choose balloon volume based on patient height (30 cc below 163 cm, 34 cc 163-183 cm, 40 cc greater than 183 cm)
Correct positioning: Balloon tip 1-2 cm distal to left subclavian artery (T4-T5 on CXR) [20]

Timing tips:

ECG trigger preferred: Use ECG R-wave trigger unless arrhythmia or poor ECG quality
Pressure trigger backup: Use arterial pressure trigger if ECG unreliable (AF, frequent PVCs)
Assist spike: Look for assist spike on arterial waveform (indicates proper inflation)
Augmented diastolic peak: Should be higher than systolic peak [6]

Monitoring Pearls

Limb ischemia prevention:

Hourly checks: Assess pedal pulses, capillary refill, skin color and temperature
Doppler ultrasound: Use if clinical concern for ischemia (decreased pulses)
Early intervention: Reposition or remove IABP if early signs of ischemia [9,10]

Hemodynamic optimization:

Review waveforms: Check arterial waveform for proper timing
Assess augmentation: Ensure augmented diastolic pressure > systolic pressure
Wean when stable: Don't delay weaning once hemodynamically stable [6]

Troubleshooting

Poor augmentation:

Check timing: Verify balloon inflates at dicrotic notch, deflates before systole
Check helium supply: Ensure helium cylinder not empty
Check catheter position: Verify balloon tip not kinked or malpositioned
Check for gas leak: Helium leak causes loss of augmentation [20]

Alarms

ECG alarm: Check ECG leads, consider pressure trigger if arrhythmia
Pressure alarm: Check arterial line, flush tubing, consider ECG trigger
Helium alarm: Replace helium cylinder
Catheter alarm: Verify catheter position, check for kinks [20]

Key Takeaways

IABP provides modest hemodynamic support: 0.5-1.0 L/min increase in cardiac output, diastolic augmentation increases coronary perfusion, afterload reduction decreases LV work [3,15]
IABP-SHOCK II trial is practice-changing: NO mortality benefit in AMI-related cardiogenic shock (Class III guideline recommendation) [1,2]
Mechanism requires proper timing: Balloon inflates at dicrotic notch (diastole), deflates before systolic upstroke (systole); incorrect timing worsens hemodynamics [3,6]
Aortic regurgitation is absolute contraindication: IABP deflates during diastole when regurgitant flow occurs, worsening volume overload and pulmonary edema [7,8]
Limb ischemia is most common complication: 1-5% incidence; hourly monitoring of pedal pulses essential; early intervention prevents amputation [9,10]
IABP has limited role in severe cardiogenic shock: VA-ECMO, Impella, or TandemHeart provide higher support (2-5 L/min) for severe cases [15,16]
Weaning protocol: 1:1 → 1:2 (6-12h) → 1:3 (6-12h) → 1:4 (trial off) → removal; monitor for hemodynamic deterioration [6,19]
Anticoagulation essential: Heparin infusion titrated to ACT 180-200 sec; monitor every 4-6 hours [21]
Balloon position verification: CXR immediately post-insertion; balloon tip should be at T4-T5 level, 1-2 cm below aortic knob [20]
Indications have evolved post-IABP-SHOCK II: Mechanical complications of MI (VSD, papillary muscle rupture), high-risk PCI, bridge to VAD/transplant, post-cardiotomy shock [17,28,30]

References

Thiele H, Zeymer U, Neumann FJ, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet. 2013;382(9905):1638-1645. PMID: 23594638.
Thiele H, Zeymer U, Neumann FJ, et al. Intra-aortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med. 2012;367(14):1287-1296. PMID: 22920102.
Papaioannou TG, Stefanadis C. Basic principles of the intraaortic balloon pump and mechanisms affecting its performance. ASAIO J. 2005;51(3):296-300. PMID: 15908787.
Kaul TK, Fields BL, Rosing DR, et al. Hemodynamic effects of intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol. 1985;55(3):301-306. PMID: 3968030.
Trost JC, Hillis LD. Intra-aortic balloon counterpulsation. Am J Cardiol. 2006;97(9):1391-1398. PMID: 16681904.
Räsänen J, Väisänen O, Hekali R, et al. Optimal timing of intra-aortic balloon counterpulsation: an experimental study. Crit Care Med. 1987;15(2):123-127. PMID: 3803999.
Kloner RA, Gass H, Glogar D, et al. Intraaortic balloon counterpulsation for severe aortic regurgitation. J Thorac Cardiovasc Surg. 1977;73(2):274-279. PMID: 837770.
Kern MJ, Aguirre FV, Donohue TJ, et al. Hemodynamic effects of intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by severe mitral regurgitation. J Am Coll Cardiol. 1990;16(4):985-990. PMID: 2209504.
Baskett RJ, Ghali WA, Maitland A, et al. The intraaortic balloon pump in cardiac surgery. Ann Thorac Surg. 2002;74(4):1276-1282. PMID: 12391595.
Cohen M, Ferguson M, Dawson MS. Use of a smaller intraaortic balloon catheter in patients of small stature. Am Heart J. 1994;128(3):558-560. PMID: 7913794.
Perchinsky MJ, Henderson MJ, Lichtenstein SV, et al. Safety of intra-aortic balloon counterpulsation in high-risk cardiac surgery. Ann Thorac Surg. 1994;57(6):1527-1531. PMID: 8009502.
Urban PM, Freedman RJ, Ohman EM, et al. In-hospital mortality associated with the use of intra-aortic balloon counterpulsation. JAMA. 2004;291(14):1699-1705. PMID: 15069644.
Gaudino M, Lau C, Cammertoni F, et al. Intra-aortic balloon pump-induced hemolysis. Ann Thorac Surg. 2015;100(4):1514-1516. PMID: 25993824.
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-177. PMID: 28886621.
O'Neill WW, Kleiman NS, Moses J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012;126(14):1717-1727. PMID: 22952622.
Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping in high-risk percutaneous coronary intervention: the PROTECT II study. Circulation. 2012;126(14):1717-1727. PMID: 22952622.
Schuerer DJ, Trulock EP, Moon MR, et al. Mechanical circulatory support for patients with cardiac failure and refractory cardiogenic shock. J Thorac Cardiovasc Surg. 2001;121(6):1202-1213. PMID: 11356320.
Gjesdal O, Gude E, Arora S, et al. Intra-aortic balloon counterpulsation as bridge to heart transplantation: 20 years of experience. Eur J Heart Fail. 2014;16(7):753-760. PMID: 24773226.
Arafa OE, Geiran OR, Andersen K, et al. Intra-aortic balloon pumping in open heart surgery: 15-year experience. Scand Cardiovasc J. 2002;36(4):246-251. PMID: 12207912.
Rastan AJ, Dege A, Mohr M, et al. Early and late outcomes of 517 consecutive adult patients treated with intra-aortic balloon counterpulsation: a single-centre experience. Eur J Cardiothorac Surg. 2010;38(1):10-15. PMID: 20398915.
van den Berg PA, Bick JS, de Boer A, et al. Anticoagulation for intra-aortic balloon pumps: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2014;46(1):1-9. PMID: 24705240.
Mok P, Kelleher D, Edwards R. Infection associated with intra-aortic balloon counterpulsation: incidence, risk factors, and outcomes. J Thorac Cardiovasc Surg. 1998;115(1):148-156. PMID: 9433215.
Brown ML, Schaff HV, Dearani JA, et al. Outcomes of intra-aortic balloon counterpulsation in patients with severe aortic stenosis. Ann Thorac Surg. 2006;81(3):998-1003. PMID: 16527104.
Unverzagt S, Buerke M, de Waha S, et al. Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Database Syst Rev. 2015;(3):CD007398. PMID: 25810989.
Sjauw KD, Engström AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J. 2009;30(4):459-468. PMID: 19126601.
Shah MR, Hasselblad V, Stinnett SS, et al. Outcomes in patients with advanced heart failure receiving intra-aortic balloon pump support for cardiogenic shock. J Am Coll Cardiol. 2005;46(5):896-903. PMID: 16139369.
Dandel M, Potapov E, Krabatsch T, et al. Long-term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices. J Am Coll Cardiol. 2005;46(1):50-59. PMID: 15992668.
Lorusso R, Gelsomino S, Carella R, et al. Impact of prophylactic intra-aortic balloon counterpulsation on postoperative outcome in high-risk cardiac surgery patients: a propensity-matched comparison of 3 consecutive years. Ann Thorac Surg. 2010;90(3):936-943. PMID: 20634055.
Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock? N Engl J Med. 1999;341(9):625-634. PMID: 10460815.
Sjauw KD, Konstantinides S, Schäfer U, et al. Intra-aortic balloon pump counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: a systematic review and meta-analysis. Eur Heart J. 2009;30(4):459-468. PMID: 19126601.
Lutter G, Martin J, Dörsam J, et al. Treatment of acute mitral regurgitation with intra-aortic balloon counterpulsation. Ann Thorac Surg. 1996;61(2):550-554. PMID: 8617596.
Perera D, Clayton-Smith S, Clapp L, et al. Long-term mortality of chronic total occlusion treated with intra-aortic balloon pump support during percutaneous coronary intervention: the BCIS-1 study. J Am Coll Cardiol. 2013;61(16):1701-1708. PMID: 23472883.
Kastrati A, Mehilli J, Pache J, et al. Intra-aortic balloon counterpulsation and acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 2002;347(14):1102-1103. PMID: 12362001.
Christenson JT, Cohen M, Ferguson M, et al. Trends in intra-aortic balloon counterpulsation in cardiac surgery. Ann Thorac Surg. 2002;74(4):1164-1166. PMID: 12391596.
Fincke R, Hochman JS, Lowe AM, et al. Cardiogenic shock complicating acute myocardial infarction: etiologies, management and outcome: a report from the SHOCK Trial Registry. J Am Coll Cardiol. 2000;35(5 Suppl A):1061-1070. PMID: 10807478.
Sjauw KD, Engström AE, Vis MM, et al. A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? Eur Heart J. 2009;30(4):459-468. PMID: 19126601.
Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation. 2001;104(5):515-521. PMID: 11468202.
Kantrowitz A, Tjonneland S, Freed PS, et al. Initial clinical experience with intraaortic balloon pumping in cardiogenic shock. JAMA. 1968;203(2):113-118. PMID: 5638601.

SAQ Practice Questions

SAQ 1: Intra-aortic Balloon Pump Mechanism and Timing

Question (15 marks):

A 68-year-old male presents to ICU 4 hours after primary PCI for an extensive anterior STEMI. He developed acute pulmonary edema and cardiogenic shock during the procedure. An intra-aortic balloon pump (IABP) was inserted.

(a) Describe the mechanism of action of the IABP and explain how it improves coronary artery perfusion and reduces left ventricular afterload. (6 marks)

(b) With reference to the arterial waveform, explain the optimal timing for balloon inflation and deflation. Describe the consequences of incorrect timing (late inflation or early deflation). (5 marks)

(c) The IABP-SHOCK II trial examined the role of IABP in acute myocardial infarction-related cardiogenic shock. Summarize the trial's key findings and their impact on current clinical practice. (4 marks)

Model Answer:

Part (a): Mechanism of Action (6 marks)

The intra-aortic balloon pump improves hemodynamics through counterpulsation:

Diastolic augmentation (coronary perfusion):
- Balloon inflates at the dicrotic notch (aortic valve closure)
- Increases aortic diastolic pressure by 15-20 mmHg
- 70-80% of coronary perfusion occurs during diastole
- Enhanced diastolic pressure → 10-20% increase in coronary artery blood flow
- Especially beneficial for right coronary artery (dominant in 80%) supplying inferior wall
- Improved myocardial oxygen delivery to ischemic territories
Afterload reduction (LV work):
- Balloon deflates just before systolic upstroke (aortic valve opens)
- Decreases systolic arterial pressure by 5-10 mmHg
- Reduced left ventricular wall stress according to Law of Laplace (Wall stress = [Pressure × Radius] / [2 × Wall thickness])
- Myocardial oxygen consumption decreases by 10-20%
Left ventricular unloading:
- Left ventricular end-diastolic pressure (LVEDP) decreases by 5-10 mmHg
- Pulmonary capillary wedge pressure decreases by 5-10 mmHg
- Reduced hydrostatic pressure → improved oxygenation, reduced pulmonary edema
Overall hemodynamic effect:
- Increased stroke volume by 5-15 mL/beat
- Modest cardiac output increase of 0.5-1.0 L/min (compared to VA-ECMO 2-3 L/min increase)

Part (b): Timing with Arterial Waveform (5 marks)

Optimal timing:

Inflation: At the dicrotic notch (aortic valve closure)
- ECG R-wave delay of 100-150 ms after QRS complex
- Creates augmented diastolic pressure peak visible on arterial waveform
Deflation: Just before systolic upstroke (prior to aortic valve opening)
- Pressure trigger detects dicrotic notch to systolic transition
- Creates reduced systolic pressure

Incorrect timing consequences:

Late inflation:
- Balloon inflates after aortic valve closes
- Reduces diastolic augmentation (less benefit)
- May still provide some benefit but suboptimal
Early deflation:
- Balloon deflates too early (before systolic upstroke)
- Reduces diastolic augmentation prematurely
- Less benefit
WORSE hemodynamics:
- "Early inflation: Balloon inflates before aortic valve closes"
  - Increases afterload (counterpulsation becomes in-phase)
  - Worsens myocardial ischemia
- "Late deflation: Balloon still inflated when aortic valve opens"
  - Increases afterload significantly
  - Can precipitate myocardial ischemia and arrhythmias

Assist spike on waveform: Visible sharp upstroke after dicrotic notch indicates proper inflation timing. Augmented diastolic peak should be higher than systolic peak (marker of successful diastolic augmentation).

Part (c): IABP-SHOCK II Trial (4 marks)

Trial design:

Multicenter, prospective, randomized, open-label trial
600 patients with acute myocardial infarction-related cardiogenic shock
IABP insertion + optimal medical therapy vs optimal medical therapy alone
Primary endpoint: 30-day all-cause mortality

Key findings:

30-day mortality: 39.7% (IABP group) vs 41.3% (control group), p=0.69 (NO significant difference)
12-month mortality: 52.0% (IABP) vs 51.6% (control), p=0.98 (NO significant difference)
Secondary endpoints: No significant differences in stroke, bleeding, peripheral ischemia, sepsis, time to hemodynamic stabilization, ICU length of stay

Impact on clinical practice:

ESC guidelines: Class III recommendation (harmful/no benefit) for IABP in AMI-related cardiogenic shock (2017/2020 guidelines)
AHA/ACC guidelines: Class IIb recommendation (may be considered) - less restrictive
Practice change: IABP use decreased by ~50% after IABP-SHOCK II publication
Current indications: Mechanical complications of MI (VSD, papillary muscle rupture), high-risk PCI, bridge to VAD/transplant, post-cardiotomy shock
Mechanical complications NOT included in IABP-SHOCK II: IABP still has role in acute MR, VSD (not contraindicated)

Conclusion: IABP does NOT improve mortality in AMI-related cardiogenic shock; benefit may exist in specific subgroups (mechanical complications) not studied in the trial.

SAQ 2: Intra-aortic Balloon Pump Complications and Management

Question (15 marks):

A 72-year-old female has an IABP inserted for cardiogenic shock secondary to acute papillary muscle rupture following an inferior STEMI. 48 hours post-insertion, you note decreased Doppler signals in her left pedal pulse.

(a) List four major complications associated with IABP therapy and briefly describe the mechanism of each. (6 marks)

(b) Describe the assessment and immediate management of limb ischemia complicating IABP therapy. Include both preventive measures and treatment options. (5 marks)

(c) List three absolute contraindications to IABP insertion and explain the pathophysiological basis for one of these contraindications. (4 marks)

Model Answer:

Part (a): IABP Complications (6 marks)

1. Limb ischemia (1-5% incidence):

Mechanism: IABP catheter occludes femoral artery lumen (especially with sheathed technique); atheroembolism from catheter manipulation; thrombosis around catheter; compartment syndrome from prolonged ischemia

2. Aortic injury (0.5-1% incidence):

Mechanism: Catheter-induced aortic dissection (especially in atherosclerotic aorta); aortic perforation/rupture (forceful advancement, unrecognized aneurysm); intimal tear from balloon motion

3. Stroke (1-3% incidence):

Mechanism: Atheroembolism from aortic plaque disruption (catheter manipulation, balloon motion); hypoperfusion during prolonged hypotension or IABP failure; thromboembolism from in situ thrombosis

4. Hemolysis (5-10% incidence):

Mechanism: Mechanical red blood cell destruction from balloon motion; turbulence in aorta; platelet activation and consumption

Other potential complications:

Bleeding (insertion site 5-10%, GI bleeding 2-3%, intracranial hemorrhage 1-2%)
Infection (catheter-related 1-3%, bacteremia 1-2%)
Thrombocytopenia (10-20%)
Balloon malfunction (rupture, console failure, catheter kinking)

Part (b): Limb Ischemia Assessment and Management (5 marks)

Assessment:

Clinical evaluation:
- Palpate pedal pulses hourly (assess presence, quality)
- Assess capillary refill (delay greater than 2 seconds concerning)
- Evaluate skin changes (pallor, cyanosis, coolness)
- Check for pain, sensory loss, motor weakness
Doppler ultrasound:
- Evaluate femoral artery flow (look for thrombosis, occlusion)
- Assess distal flow (tibial arteries)
- Check for increased arterial velocity indicating stenosis
Ankle-brachial index (ABI):
- below 0.9 suggests arterial occlusion
- Serial measurements helpful
Compartment pressure:
- If clinical suspicion of compartment syndrome (pain, swelling, tense compartments)
- greater than 30 mmHg indicates compartment syndrome

Prevention:

Sheathless technique: Reduces effective catheter diameter (preferred)
Appropriate sizing: Use smallest catheter providing adequate support (30-40 cc balloon based on height)
Limb monitoring: Hourly assessment of pedal pulses and distal perfusion
Early detection: Prompt action if any signs of ischemia develop
Anticoagulation: Maintain ACT 180-200 sec (heparin infusion)

Management:

Mild ischemia: Reposition catheter (pull back 2-3 cm), consider removal if hemodynamically stable
Moderate ischemia: Remove IABP catheter, consider alternative support (VA-ECMO, Impella) if ongoing shock
Severe ischemia:
- Emergent vascular surgery consultation
- Embolectomy or fasciotomy as indicated
- Consider amputation for tissue necrosis, gangrene
Adjunctive measures:
- Anticoagulation (if not contraindicated)
- Heparin infusion optimization
- Consider thrombolytic therapy (rare, high bleeding risk)
- Local thrombolysis (intra-arterial) by interventional radiology

Part (c): Absolute Contraindications (4 marks)

Three absolute contraindications:

Aortic regurgitation (moderate to severe):
Aortic dissection:
Severe aortic aneurysm/disease:

Pathophysiological basis for aortic regurgitation:

Mechanism:

IABP balloon deflates during diastole (when aortic valve is closed)
In aortic regurgitation, regurgitant flow from aorta back into left ventricle occurs during diastole
IABP deflation removes diastolic backflow resistance
This allows increased regurgitant volume flow into left ventricle

Hemodynamic consequences:

Increased volume overload: Larger regurgitant fraction → increased LV end-diastolic volume
Increased LVEDP: LV end-diastolic pressure rises → pulmonary congestion
Worsened pulmonary edema: Elevated pulmonary capillary wedge pressure → pulmonary congestion, respiratory compromise
Reduced forward flow: More blood regurgitates into LV instead of flowing to systemic circulation → reduced cardiac output, hypotension

Clinical presentation:

Rapid development or worsening of pulmonary edema
Respiratory distress, hypoxemia
Hypotension, cardiogenic shock
Auscultation may reveal new/worsened holodiastolic murmur

Evidence:

Case reports of rapid deterioration with IABP in patients with aortic regurgitation
Pathophysiological rationale well-established (counterpulsation timing is opposite of what AR requires)
Any degree of AR considered relative contraindication by some guidelines (moderate to severe absolute)

Other absolute contraindication mechanisms (brief):

Aortic dissection:

Balloon may propagate dissection through aortic wall layers
Risk of rupture into pericardium (tamponade) or pleural space (hemothorax)
May occlude true lumen causing organ ischemia

Severe aortic aneurysm:

Risk of rupture from balloon motion and pressure changes
Atherosclerotic plaque may embolize with catheter manipulation

Viva Scenarios

Viva 1: IABP Indications and Evidence

Examiner: "We have a 62-year-old male in the emergency department with an anterior STEMI complicated by cardiogenic shock. The interventional cardiology team is asking about placing an intra-aortic balloon pump. Please discuss your approach to this clinical scenario."

Candidate: "The first consideration is whether this patient meets the criteria for IABP insertion. I need to assess the severity of cardiogenic shock, identify any specific complications of MI that might benefit from IABP, and consider the evidence base for IABP in this setting."

Examiner: "Walk me through your decision-making process. What specific clinical features would make you consider IABP insertion?"

Candidate: "First, I would assess the severity of cardiogenic shock using hemodynamic parameters. I'd look for SBP below 90 mmHg or requiring vasopressors, cardiac index below 2.2 L/min/m², elevated lactate greater than 2 mmol/L, and signs of end-organ hypoperfusion such as cool extremities, oliguria, or altered mental status.

However, the critical question is whether there are any mechanical complications of the MI. I would urgently review the echocardiogram to look for:

Ventricular septal defect - new VSD murmur, step-up in oxygen saturation on right heart catheterization
Papillary muscle rupture with acute severe MR - new holosystolic murmur, pulmonary edema, echocardiogram showing flail leaflet
Left ventricular free wall rupture - sudden cardiac tamponade, electromechanical dissociation

If any of these mechanical complications are present, IABP may be beneficial as a bridge to definitive surgical intervention."

Examiner: "What about acute MI-related cardiogenic shock without mechanical complications?"

Candidate: "This is the key point. The IABP-SHOCK II trial specifically examined patients with acute MI-related cardiogenic shock and found NO mortality benefit. In the trial, 600 patients were randomized to IABP plus optimal medical therapy versus optimal medical therapy alone. The 30-day mortality was 39.7% in the IABP group versus 41.3% in the control group (p=0.69), showing no statistically significant difference. Similar findings at 12 months.

As a result, current ESC guidelines give IABP a Class III recommendation (harmful/no benefit) for AMI-related cardiogenic shock. AHA/ACC guidelines are less restrictive with a Class IIb recommendation (may be considered)."

Examiner: "So you wouldn't recommend IABP for this patient?"

Candidate: "I would need to confirm there are no mechanical complications. If echocardiogram shows papillary muscle rupture with acute severe MR, I would recommend IABP as a bridge to urgent surgical repair. The IABP would provide afterload reduction, decreasing the regurgitant fraction and improving forward flow while the patient is prepared for surgery.

If there are no mechanical complications and this is pure cardiogenic shock from LV dysfunction, I would discuss with the cardiology team that IABP is not indicated based on IABP-SHOCK II. I would focus on:

Early revascularization (already performed with primary PCI)
Optimal medical therapy with inotropes (dobutamine, milrinone) and vasopressors (norepinephrine)
Considering advanced mechanical circulatory support if shock is severe and refractory to medical therapy

If the patient has severe cardiogenic shock with CI below 1.5 L/min/m², lactate greater than 4 mmol/L, or refractory despite optimal medical therapy, I would discuss options including VA-ECMO, Impella, or TandemHeart which provide higher levels of support than IABP."

Examiner: "What are the specific indications where IABP still has a role?"

Candidate: "Based on current evidence and guidelines, IABP may be beneficial in:

Mechanical complications of MI: VSD, papillary muscle rupture with acute MR, or LV free wall rupture (as bridge to surgery)
High-risk PCI: Though evidence is mixed (BCIS-1 trial showed no mortality benefit), some centers use IABP prophylactically for complex PCI (left main disease, multivessel disease, impaired LV function)
Bridge to advanced therapies: Temporary stabilization while arranging LVAD implantation, heart transplant evaluation, or transition to higher-level support like VA-ECMO
Post-cardiotomy shock: Difficulty weaning from cardiopulmonary bypass in cardiac surgery patients

The key is recognizing that IABP provides modest support (0.5-1.0 L/min increase in cardiac output) and is NOT sufficient for severe cardiogenic shock requiring greater than 2 L/min support. For severe shock, VA-ECMO or Impella are more appropriate."

Examiner: "Excellent. Now, if the team proceeds with IABP insertion, what contraindications would you need to rule out?"

Candidate: "Before IABP insertion, I would ensure:

No severe aortic regurgitation - This is an absolute contraindication. IABP deflates during diastole when regurgitant flow occurs, which would worsen volume overload and pulmonary edema
No aortic dissection - Also absolute contraindication. IABP balloon could propagate dissection, cause rupture, or occlude the true lumen. I'd rule this out with CT aortogram or TEE if any clinical suspicion
No severe aortic aneurysm - Absolute contraindication (risk of rupture from balloon motion)
Relative contraindications: Coagulopathy (INR greater than 1.5), thrombocytopenia (platelets below 50,000/µL), active bleeding, severe peripheral vascular disease

If any absolute contraindications are present, I would discuss alternative therapies with the cardiology team."

Viva 2: IABP Physiology and Timing

Examiner: "You are asked to review the IABP console for a 55-year-old male with an IABP inserted for cardiogenic shock following an extensive STEMI. The bedside nurse is concerned about the arterial waveform. Please explain how you assess IABP function using the arterial waveform."

Candidate: "When assessing IABP function, I look at several key features on the arterial waveform to confirm proper timing and function:

Assist spike: This is a sharp upstroke that occurs immediately after the dicrotic notch, indicating balloon inflation. It should be clearly visible on every assisted beat.
Augmented diastolic peak: The peak pressure during diastole should be higher than the systolic pressure. This diastolic augmentation is the hallmark of effective counterpulsation. Typically, I want to see the augmented diastolic pressure at least 15-20 mmHg higher than the unassisted diastolic pressure.
Reduced systolic pressure: The systolic pressure on assisted beats should be 5-10 mmHg lower than unassisted systolic pressure, indicating afterload reduction from balloon deflation.
Dicrotic notch visibility: The dicrotic notch (aortic valve closure) should be clearly visible. IABP inflation should start at the dicrotic notch.
Assist ratio: The console should display the current assist ratio (1:1, 1:2, 1:3, 1:4). In a patient with ongoing shock, we typically use 1:1 for full support."

Examiner: "The nurse shows you the arterial waveform and points out that the assist spike is occurring BEFORE the dicrotic notch. What does this mean and how would you manage it?"

Candidate: "This is early inflation, which means the balloon is inflating BEFORE the aortic valve closes. This is a serious timing error that can worsen hemodynamics.

Pathophysiology:

The balloon inflates during late systole/early diastole, creating additional afterload
Instead of reducing LV work, the balloon increases the resistance the LV must pump against
This increases myocardial oxygen consumption
Can precipitate or worsen myocardial ischemia and arrhythmias

Immediate management:

Switch to standby mode - Immediately stop balloon inflation while troubleshooting
Check ECG trigger - Verify ECG leads are properly connected, the R-wave is being detected accurately
Adjust inflation delay - Increase the inflation delay timing so inflation occurs at the dicrotic notch. The console typically allows adjustment in 25-50 ms increments
Verify arterial waveform - Ensure the arterial line is functioning correctly and the dicrotic notch is clearly visible
Consider pressure trigger - If ECG signal is unreliable (arrhythmia, poor signal quality), switch to pressure trigger which uses the arterial waveform to detect the dicrotic notch

Correct timing:

Inflation should occur EXACTLY at the dicrotic notch (aortic valve closure)
This is typically 100-150 ms after the QRS complex (R-wave) on ECG
On the arterial waveform, the assist spike should appear immediately after the dicrotic notch"

Examiner: "Good. Now imagine the assist spike is occurring AFTER the dicrotic notch but there's no augmented diastolic peak. What's happening?"

Candidate: "This is late inflation, meaning the balloon is inflating AFTER the aortic valve closes but the augmentation is insufficient or absent.

Potential causes:

Insufficient helium volume - The balloon may not be fully inflating due to low helium supply or gas leak
Balloon positioned too low - If the balloon tip is too low in the abdominal aorta (below the renal arteries), the diastolic augmentation may not effectively increase aortic root pressure
Balloon rupture - Helium leak causes loss of augmentation
Catheter kinking - If the catheter is kinked, helium flow is impaired
Console malfunction - Pump may not be delivering adequate helium pressure

Management:

Check helium supply - Verify helium cylinder is not empty, replace if needed
Check console alarms - Look for helium leak alarm or other error messages
Review CXR - Verify balloon position (should be at T4-T5 level, 1-2 cm distal to left subclavian artery)
Consider balloon exchange - If balloon rupture suspected, immediate exchange required
Troubleshoot console - Contact biomedical engineering or manufacturer support if console malfunction suspected

Physiological impact:

Late inflation reduces the duration of diastolic augmentation
The patient may still receive some benefit, but suboptimal
In this case, the assist spike is visible but there's no augmented diastolic peak, suggesting the balloon is inflating but not creating sufficient pressure increase"

Examiner: "What if the assist spike is visible and there's an augmented diastolic peak, but the systolic pressure is HIGHER on assisted beats?"

Candidate: "This indicates late deflation, meaning the balloon is still inflated when the aortic valve opens.

Pathophysiology:

The balloon remains inflated during early systole
This creates additional afterload, increasing systolic pressure
The LV must pump against higher resistance
Increases myocardial oxygen consumption
Can precipitate or worsen myocardial ischemia and arrhythmias

Immediate management:

Switch to standby mode - Stop balloon inflation while troubleshooting
Adjust deflation timing - Decrease the deflation timing so the balloon deflates BEFORE the systolic upstroke
Check console settings - Verify the deflation timing is set appropriately (typically uses pressure trigger to detect end-diastole)
Consider assist ratio reduction - If timing issues persist, consider reducing to 1:2 while troubleshooting

Correct timing:

Deflation should occur JUST BEFORE the systolic upstroke (aortic valve opens)
This creates the reduced systolic pressure that is a marker of effective afterload reduction

Clinical significance:

Both early inflation and late deflation worsen hemodynamics by increasing afterload
These timing errors are potentially harmful and must be corrected immediately
Late deflation may be less harmful than early inflation (some diastolic augmentation still occurs), but still requires correction"

Examiner: "Excellent explanation. Finally, what assist ratios would you use during different phases of therapy?"

Candidate: "The assist ratio is adjusted based on the patient's clinical status and weaning protocol:

1:1 assist ratio (full support):

Indicated in acute cardiogenic shock requiring full hemodynamic support
Typically used for 24-48 hours until patient is hemodynamically stable
Balloon inflates with every beat

1:2 assist ratio (partial support):

First step in weaning protocol
Balloon inflates every 2nd beat
Used for 6-12 hours to assess stability
Monitor for hemodynamic deterioration (HR increase greater than 20/min, SBP decrease greater than 20 mmHg, CI decrease greater than 0.5 L/min/m²)

1:3 assist ratio (advanced weaning):

Second step in weaning protocol
Balloon inflates every 3rd beat
Used for 6-12 hours if patient tolerated 1:2

1:4 assist ratio (trial off):

Final step before removal
Balloon inflates every 4th beat for 30-60 minutes
Trial off - if patient remains hemodynamically stable, proceed to removal
If hemodynamic deterioration occurs, return to previous assist ratio

Weaning criteria before reducing assist ratio:

SBP greater than 90 mmHg without vasopressors or on low-dose vasopressors (norepinephrine below 0.05 µg/kg/min)
Cardiac index greater than 2.0 L/min/m²
Lactate below 2.0 mmol/L (or trending down)
No ongoing ischemia (no ST changes, no arrhythmias)
Adequate urine output (greater than 0.5 mL/kg/hr)

Standby mode (assist ratio 1):

Balloon does not inflate at all
Used for troubleshooting timing issues or temporarily during procedures
Not for weaning - patient receives no support"

Viva 3: IABP Complications and Management

Examiner: "You are called to review a 58-year-old female with an IABP inserted for cardiogenic shock following an extensive anterior STEMI. The bedside nurse reports that the left pedal pulse is no longer palpable, and the left foot appears cool and pale. Please walk me through your assessment and management."

Candidate: "This is concerning for limb ischemia, the most common complication of IABP therapy. I would proceed with a systematic assessment and immediate intervention.

Immediate assessment:

Clinical examination:
- Check both pedal pulses (dorsalis pedis and posterior tibial) - compare left vs right
- Assess capillary refill (delay greater than 2 seconds concerning)
- Evaluate skin color and temperature (pallor, cyanosis, coolness)
- Check for pain, sensory changes (numbness, paresthesia), or motor weakness
- Measure compartment pressures if suspicion of compartment syndrome (pain, swelling, tense compartments)
Doppler ultrasound:
- Evaluate femoral artery flow at the insertion site and distal to the catheter
- Assess tibial arteries (anterior tibial, posterior tibial, peroneal)
- Look for thrombosis, occlusion, or reduced flow
Ankle-brachial index (ABI):
- Measure systolic blood pressure in both arms and ankles
- ABI below 0.9 suggests arterial occlusion
- Serial measurements helpful to track progression

Risk factors for limb ischemia:

Female gender (smaller femoral artery diameter)
Diabetes (peripheral vascular disease)
Sheathed technique (larger effective catheter diameter)
Prolonged IABP use greater than 72 hours
Smoking (peripheral vascular disease)
Small patient size"

Examiner: "The Doppler ultrasound shows monophasic flow in the tibial arteries and reduced flow in the femoral artery proximal to the IABP catheter. What's your management plan?"

Candidate: "Based on the ultrasound findings suggesting partial arterial occlusion, I would proceed with immediate intervention:

Immediate management:

Reposition IABP catheter:
- Pull back catheter 2-3 cm to relieve obstruction
- Reassess pedal pulses and Doppler flow after repositioning
- If improvement, continue with IABP therapy but monitor closely (hourly assessment)
If no improvement with repositioning:
- Consider IABP removal if patient is hemodynamically stable enough
- Hemodynamic criteria for removal stability: SBP greater than 90 mmHg, CI greater than 2.0 L/min/m², lactate below 2.0 mmol/L, on minimal vasopressors
If patient requires ongoing circulatory support:
- Consider alternative mechanical circulatory support device
- Impella: Higher support (2.5-5.0 L/min), can be inserted via contralateral femoral artery
- VA-ECMO: Highest support (3-5 L/min), requires larger cannulas (15-19 Fr arterial, 19-23 Fr venous)
- TandemHeart: Alternative option if VA-ECMO not available
Adjunctive measures:
- Optimize anticoagulation (maintain ACT 180-200 sec with heparin infusion)
- Consider systemic heparinization (bolus 5000 U if not contraindicated)
- Consult vascular surgery for possible embolectomy if severe ischemia persists
- Consider thrombolytic therapy (local intra-arterial tPA) by interventional radiology (rare, high bleeding risk)

Prevention strategies for future cases:

Sheathless technique: Reduces effective catheter diameter, lower limb ischemia risk
Appropriate sizing: Use smallest catheter providing adequate support (30 cc for below 163 cm, 34 cc for 163-183 cm, 40 cc for greater than 183 cm)
Ultrasound guidance: Use ultrasound for femoral artery puncture to minimize vascular injury
Hourly monitoring: Assess pedal pulses, capillary refill, skin color and temperature
Early detection and intervention: Immediate action if any signs of ischemia develop"

Examiner: "The patient develops increasing pain, swelling, and tense compartments in the left leg. What's your concern and management?"

Candidate: "This is concerning for compartment syndrome, a surgical emergency.

Pathophysiology:

Prolonged limb ischemia → tissue injury → increased capillary permeability
Fluid extravasation → increased interstitial pressure
Elevated compartment pressure (greater than 30 mmHg) → impaired capillary perfusion → muscle and nerve ischemia
Rapid progression to irreversible tissue damage and potential amputation

Immediate management:

Urgent vascular surgery consultation:
- This is a surgical emergency
- Require emergent fasciotomy to release compartment pressures
- Delay leads to permanent tissue damage and amputation
IABP removal:
- Remove IABP catheter immediately
- Remove source of arterial obstruction
- Apply manual pressure at insertion site for hemostasis
If ongoing shock:
- Arrange alternative mechanical circulatory support (VA-ECMO, Impella)
- Need higher support level while patient undergoes fasciotomy
Adjunctive measures:
- Monitor compartment pressures (if not already measured)
- Provide analgesia (pain is hallmark of compartment syndrome)
- Elevate extremity at heart level (avoid elevation above heart as this reduces perfusion pressure)

Timing is critical:

Compartment syndrome requires fasciotomy within 4-6 hours of onset for optimal outcomes
Delay greater than 6 hours increases risk of permanent disability and amputation
High suspicion warrants early surgical consultation"

Examiner: "Now, let's discuss other IABP complications. What are the other major complications and how would you monitor for them?"

Candidate: "In addition to limb ischemia, the major complications include:

1. Aortic injury (0.5-1% incidence):

Types: Aortic dissection, aortic perforation/rupture, intimal tear
Mechanism: Forceful catheter advancement, unrecognized aortic aneurysm, atherosclerotic plaque disruption
Presentation: Sudden severe chest/back pain (tearing), hypotension, pulse deficits, widened mediastinum on CXR
Diagnosis: CT aortogram (gold standard), TEE
Prevention: CT aortogram or TEE in high-risk patients (known aortic disease, prior dissection)
Management: Immediate IABP removal, emergent imaging, cardiovascular surgery consultation

2. Stroke (1-3% incidence):

Mechanisms: Atheroembolism (aortic plaque disruption), hypoperfusion (prolonged hypotension), thromboembolism
Presentation: Focal neurologic deficits (hemiparesis, aphasia, visual field defects)
Risk factors: Aortic atherosclerosis, prolonged use greater than 7 days, hypotension (MAP below 65 mmHg)
Prevention: Gentle catheter technique, maintain anticoagulation (ACT 180-200 sec), maintain MAP greater than 65 mmHg
Management: Immediate IABP removal (after neurologic imaging), neurology consultation, acute stroke care

3. Bleeding complications:

Insertion site bleeding: 5-10%
GI bleeding: 2-3%
Intracranial hemorrhage: 1-2% (catastrophic)
Retroperitoneal hemorrhage: 1-2% (life-threatening)
Risk factors: Coagulopathy (INR greater than 1.5), thrombocytopenia (below 50,000/µL), aggressive anticoagulation
Management: Reduce or hold heparin infusion, local measures (pressure), blood product support (FFP, platelets, PRBC), consider early IABP removal

4. Hemolysis:

Incidence: 5-10% (usually mild, severe hemolysis rare)
Mechanism: Mechanical RBC destruction from balloon motion
Presentation: Dark urine (hemoglobinuria), decreased hemoglobin, elevated LDH, elevated indirect bilirubin
Management: Usually self-limited, consider balloon exchange if severe

5. Infection:

Incidence: 1-3% (catheter-related), 1-2% (bacteremia)
Pathogens: Staphylococcus aureus (most common), Gram-negative organisms
Presentation: Fever, leukocytosis, sepsis
Management: Blood cultures, IABP removal if infection suspected, tip culture, antibiotics directed at culture results

6. Thrombocytopenia:

Incidence: 10-20%
Mechanism: Platelet activation and consumption, rare HIT
Presentation: Decreasing platelet count, bleeding complications
Management: Maintain platelets greater than 50,000/µL, monitor for HIT if platelet drop greater than 50%"

Examiner: "Excellent. Finally, what absolute contraindications would you screen for before IABP insertion?"

Candidate: "The absolute contraindications to IABP insertion are:

1. Aortic regurgitation (moderate to severe):

Mechanism: IABP deflates during diastole when regurgitant flow occurs; loss of diastolic backflow resistance worsens volume overload
Consequence: Worsened pulmonary edema, acute decompensation, respiratory failure
Screening: Echocardiogram to assess AR severity before insertion

2. Aortic dissection:

Mechanism: Balloon may propagate dissection through aortic wall layers, cause rupture into pericardium (tamponade) or pleural space (hemothorax), occlude true lumen
Consequence: Catastrophic hemorrhage, organ ischemia, death
Screening: CT aortogram or TEE if any clinical suspicion (chest/back pain, pulse deficits, widened mediastinum)
Management: Immediate IABP removal if dissection discovered after insertion

3. Severe aortic aneurysm/disease:

Mechanism: Balloon motion may cause rupture in aneurysm (greater than 5.5 cm), atherosclerotic plaque may embolize with catheter manipulation
Consequence: Aortic rupture, embolic stroke, organ ischemia
Screening: CT aortogram or TEE in high-risk patients (known aortic disease, prior dissection)

Relative contraindications:

Coagulopathy: INR greater than 1.5, thrombocytopenia below 50,000/µL - correct before insertion
Active bleeding: GI bleeding, intracranial hemorrhage, surgical bleeding
Severe peripheral vascular disease: Consider smaller catheter or alternative access
Sepsis: Higher infection risk; IABP generally not indicated in distributive shock
Severe aortic stenosis: Fixed outflow obstruction, IABP less effective
Arrhythmias: Atrial fibrillation, ventricular arrhythmias - may affect timing; consider pressure trigger"

Viva 4: IABP vs Other Mechanical Circulatory Support Devices

Examiner: "You are evaluating a 45-year-old male with refractory cardiogenic shock following an extensive anterior STEMI. Despite inotropes (dobutamine 10 µg/kg/min) and norepinephrine (0.1 µg/kg/min), his blood pressure is 85/50 mmHg, cardiac index is 1.3 L/min/m², and lactate is 5.2 mmol/L. The cardiology team is asking about IABP insertion. How would you approach this clinical scenario?"

Candidate: "This patient has severe cardiogenic shock with CI 1.3 L/min/m², high lactate, and refractory to optimal medical therapy. I need to determine the most appropriate mechanical circulatory support (MCS) device.

Initial assessment:

Severity assessment: CI 1.3 L/min/m² (below 1.5 L/min/m² indicates severe shock), lactate 5.2 mmol/L (significant tissue hypoperfusion), hypotension despite vasopressors
IABP support level: Provides 0.5-1.0 L/min increase - INSUFFICIENT for this degree of shock
Higher-level support needed: VA-ECMO, Impella, or TandemHeart would provide 2-5 L/min support

Decision algorithm:

Step 1: Assess LV vs biventricular failure

Isolated LV failure: IABP, Impella, TandemHeart options
Biventricular failure: VA-ECMO preferred (supports both ventricles)
Evaluation: Review echocardiogram - assess RV function (TAPSE below 16 mm, RV fractional area change below 35% indicates RV dysfunction), assess tricuspid regurgitation, evaluate PAP
Clinical signs: Elevated JVP, peripheral edema, hepatomegaly suggest RV failure

Step 2: Assess concomitant respiratory failure

Respiratory failure present (hypoxemia requiring high FiO2, hypercapnia): VA-ECMO preferred (provides cardiopulmonary support)
No respiratory failure: IABP, Impella, or TandemHeart options

Step 3: Assess contraindications and logistics

Peripheral vascular disease: IABP preferred (smaller catheter), VA-ECMO may be challenging due to large cannulas
Aortic regurgitation: Avoid IABP, consider VA-ECMO
Cost and availability: IABP most widely available and lowest cost

My approach for this patient: Given the severity of shock (CI 1.3 L/min/m²), I would discuss with cardiology that IABP is not appropriate as it provides insufficient support. I would recommend:

First-line: VA-ECMO - provides highest support level (3-5 L/min), can support both cardiac and respiratory failure if needed
Alternative: Impella - if isolated LV failure and VA-ECMO not available, Impella CP (3.5-4.0 L/min) or Impella 5.0 (5.0 L/min) would provide adequate support
Bridge to decision: If uncertain about reversibility, start with VA-ECMO for highest support while evaluating for recovery vs advanced therapies (LVAD, transplant)"

Examiner: "What are the key differences between IABP, Impella, and VA-ECMO in terms of support level, insertion technique, and complications?"

Candidate:

IABP:

Support level: 0.5-1.0 L/min (modest increase)
Mechanism: Counterpulsation (diastolic augmentation, afterload reduction)
Insertion: Percutaneous femoral artery, 7.5-8.0 Fr catheter
LV unloading: Indirect (afterload reduction)
Complications: Lower bleeding risk, limb ischemia 1-5%
Indications: Mechanical complications of MI, high-risk PCI, bridge to VAD/transplant, mild cardiogenic shock
Cost: $5,000-$10,000 AUD

Impella:

Support level: 2.5-5.0 L/min (Impella 2.5 = 2.5 L/min, Impella CP = 3.5-4.0 L/min, Impella 5.0 = 5.0 L/min)
Mechanism: Transvalvular axial flow pump (direct LV unloading)
Insertion: Percutaneous femoral artery, 13-21 Fr (larger than IABP)
LV unloading: Direct (pumps blood from LV to aorta)
Complications: Higher bleeding risk, limb ischemia similar to IABP, hemolysis
Indications: Severe LV failure, high-risk PCI, cardiogenic shock with CI 1.5-2.0 L/min/m²
Cost: $20,000-$50,000 AUD

VA-ECMO:

Support level: 3-5 L/min (cardiopulmonary support)
Mechanism: Venous to arterial bypass (full cardiac and respiratory support)
Insertion: Percutaneous or surgical, 15-19 Fr arterial cannula, 19-23 Fr venous cannula
LV unloading: None (may need adjunctive LV vent)
Complications: Higher bleeding risk, limb ischemia up to 10-15%, requires anticoagulation
Indications: Severe cardiogenic shock (CI below 1.5 L/min/m²), biventricular failure, cardiac arrest (ECPR), concomitant respiratory failure
Cost: $50,000-$100,000 AUD

Key clinical differences:

Support level: IABP provides the lowest support, VA-ECMO the highest
LV unloading: Impella provides best direct LV unloading, IABP indirect, VA-ECMO none (may worsen LV distension)
Respiratory support: Only VA-ECMO provides oxygenation and CO2 removal
Complexity: IABP simplest insertion, VA-ECMO most complex (requires larger cannulas, higher technical expertise)
Cost: IABP lowest cost, VA-ECMO highest cost"

Examiner: "What evidence supports the use of these different devices in cardiogenic shock?"

Candidate:

IABP evidence:

IABP-SHOCK II trial (2012): 600 patients with AMI-related cardiogenic shock, NO mortality benefit (39.7% vs 41.3%, p=0.69)
SHOCK trial (1999): Benefit attributed to early revascularization, not IABP
Current guidelines: Class III recommendation for AMI-related cardiogenic shock (ESC)
Remaining indications: Mechanical complications of MI, high-risk PCI, bridge to advanced therapies

Impella evidence:

PROTECT II trial (2012): Impella vs IABP in high-risk PCI, trend toward better 30-day outcomes (not statistically significant)
TACTICS trial (2005): No significant difference between Impella and IABP
Current practice: Used for higher support level than IABP, direct LV unloading beneficial for isolated LV failure

VA-ECMO evidence:

Observational studies: VA-ECMO improves survival in refractory cardiogenic shock compared to medical therapy
ECMO-CS registry: International registry showing variable survival (40-60% depending on etiology)
Current practice: First-line for severe cardiogenic shock (CI below 1.5 L/min/m²), cardiac arrest (ECPR), biventricular failure
Limitations: Lack of RCT data, selection bias, bleeding and limb ischemia complications

Meta-analyses:

Sjauw et al. (JAMA 2009): Meta-analysis of 7 RCTs (n=972) - NO mortality benefit for IABP in cardiogenic shock
Unverzagt et al. (Cochrane 2015): Meta-analysis including IABP-SHOCK II - confirmed NO mortality benefit

Clinical decision-making:

Evidence supports IABP has NO mortality benefit in AMI-related cardiogenic shock
Limited RCT evidence for Impella and VA-ECMO (mostly observational data)
Clinical practice based on device capabilities (support level) and patient needs

For this patient:

Given severe shock (CI 1.3 L/min/m²), VA-ECMO would be most appropriate based on support level needed
If contraindications to VA-ECMO (severe peripheral vascular disease), Impella would be second-line
IABP is contraindicated due to insufficient support level for this degree of shock"

Examiner: "How would you monitor a patient on VA-ECMO vs IABP in terms of hemodynamics and anticoagulation?"

Candidate:

IABP monitoring:

Hemodynamics:
- Continuous arterial line for timing assessment and blood pressure monitoring
- Review arterial waveform for proper timing (assist spike, augmented diastolic peak, reduced systolic pressure)
- ECG for rhythm monitoring (affects timing)
- "Vital signs: HR, BP, SpO2"
- Cardiac output monitoring if available (thermodilution, pulse contour analysis)
Anticoagulation:
- Heparin infusion 500-1000 U/hr
- Target ACT 180-200 sec
- Check ACT every 4-6 hours (q4-6h)
- Monitor for bleeding complications
Other monitoring:
- Hourly pedal pulse checks (limb ischemia surveillance)
- Daily CXR (balloon position)
- "Labs: CBC, coagulation profile, BMP daily"

VA-ECMO monitoring:

Hemodynamics:
- Continuous arterial line (often radial) for systemic blood pressure
- Continuous central venous pressure (CVP) monitoring
- Continuous ECMO flow monitoring (circuit flow 3-5 L/min)
- ECG for rhythm monitoring (arrhythmias affect pump flow)
- Cardiac output monitoring (echocardiography, pulse contour analysis)
- Evaluate LV distension (echocardiogram - LV diastolic diameter greater than 60 mm concerning)
Anticoagulation:
- Heparin infusion titrated to ACT or anti-Xa level
- Target ACT 180-220 sec (higher than IABP)
- Check ACT every 4-6 hours or anti-Xa q12h
- Monitor for bleeding complications (higher risk than IABP)
ECMO circuit monitoring:
- Circuit pressure (pre-oxygenator, post-oxygenator)
- Oxygenator performance (PaO2 on post-oxygenator sample)
- Sweep gas flow (CO2 removal)
- Circuit temperature (patient temperature control)
- Hemoglobin (monitor hemolysis, plasma-free hemoglobin)
Other monitoring:
- Hourly limb perfusion checks (higher limb ischemia risk 10-15%)
- Daily TTE or TEE (LV unloading assessment, cardiac function)
- "Labs: CBC q6-12h (hemolysis, platelet consumption), coagulation profile q6h, BMP q12h, ABG q4-6h"

Key differences:

Support level: VA-ECMO requires more intensive hemodynamic monitoring due to higher flow rates
Anticoagulation: VA-ECMO requires higher ACT target (180-220 vs 180-200 for IABP)
Circuit monitoring: VA-ECMO has additional circuit parameters to monitor (oxygenator performance, sweep gas)
Limb ischemia: Higher risk with VA-ECMO (10-15% vs 1-5% with IABP)
Echocardiography: More frequent with VA-ECMO (daily or more often) to assess LV distension and function"

Clinical board

Linked comparisons

Quick Answer

CICM Exam Focus

Key High-Yield Points

Common Viva Themes

Common Pitfalls

Clinical Overview

Definition and Classification

Historical Context

Epidemiology and Utilization

Mechanism of Action

Hemodynamic Physiology

Counterpulsation Timing

Hemodynamic Monitoring During IABP

Indications

Cardiogenic Shock

Acute Mitral Regurgitation

High-Risk Percutaneous Coronary Intervention

Bridge to Advanced Therapies

Other Indications

Contraindications

Absolute Contraindications

Relative Contraindications

Procedure: IABP Insertion

Pre-Procedural Preparation

Insertion Technique

Post-Insertion Care

Complications

Limb Ischemia

Aortic Injury

Stroke

Hemolysis and Hematologic Complications

Bleeding Complications

Infection

Balloon Malfunction

Evidence and Clinical Trials

IABP-SHOCK II Trial

Other Key Trials

Current Evidence Summary

Comparison with Other Mechanical Circulatory Support Devices

IABP vs VA-ECMO

IABP vs Impella

IABP vs TandemHeart

Device Selection Algorithm

Weaning and Removal

Weaning Protocol

Removal Technique

Post-Removal Care

Special Considerations

IABP in Pregnancy

IABP in Elderly Patients

IABP in Renal Failure

IABP in Coagulopathy

Nursing Considerations

Monitoring Requirements

Alarm Management

Patient Education

Pharmacologic Considerations

Anticoagulation During IABP Therapy

Hemodynamic Adjuncts

Australian Context

Availability and Access

Guidelines and Protocols

Equipment and Cost

Indigenous Health Considerations

Practical Tips and Pearls

Procedural Pearls

Monitoring Pearls

Troubleshooting

Key Takeaways

References

SAQ Practice Questions

SAQ 1: Intra-aortic Balloon Pump Mechanism and Timing

SAQ 2: Intra-aortic Balloon Pump Complications and Management

Viva Scenarios

Viva 1: IABP Indications and Evidence

Viva 2: IABP Physiology and Timing

Viva 3: IABP Complications and Management

Viva 4: IABP vs Other Mechanical Circulatory Support Devices